EndoTODAY | EndoATLAS | OPD

Parasite | Eso | Sto | Cancer | ESD

Boxim | DEX | Sono | Schedule

Home | Recent | Blog | Links

EndoTODAY ³»½Ã°æ ±³½Ç


[È­¿äÀú³ÎŬ·´. Tuesday journal club]

½Ã°£°ú Àå¼Ò: ¸ÅÁÖ È­¿äÀÏ ¿ÀÀü 7½Ã 30ºÐ 8Ãþ ȸÀǽÇ

³»¿ë: (1) Áõ·Ê °ËÅä, (2) Àú³Î ¸®ºä, (3) Research progress, (4) ±âŸ ³íÀÇ

³»½Ã°æ °ü·Ã ºÎºÐº° ´ã´ç: ÁßȯÀÚ½Ç/¼ö¼úÀå/portable (¹Î¾ç¿ø), ÀÔ¿øȯÀÚ ³»½Ã°æ (ÀÌÇõ), ÀÀ±Þ½Ç (±èÅÂÁØ), ³»½Ã°æ ½Ã½ºÅÛ (¹Îº´ÈÆ), Ç×ÀÀ°íÁ¦/Ç×Ç÷¼ÒÆÇÁ¦/PEG (±èÀº¶õ), ´ëÀå³»½Ã°æ (È«¼º³ë)

Áý´ãȸ: ¿ù¿ä¼ÒÈ­±âÁý´ãȸ (±èÅÂÁØ), È­¿äÀú³ÎŬ·´ (ÀÌÇõ), ¸ñ¿ä³»½Ã°æÁý´ãȸ (ÀÌÁØÇà), ³»½Ã°æ°£È£¼¼¹Ì³ª (¹Î¾ç¿ø), Winter school (¹Îº´ÈÆ)


2017-12-5

[Àú³Î] Metaplasia: tissue injury adaptation and a precursor to the dysplasia-cancer sequence. Nat Rev Cancer. 2017

[ÀÌÁØÇà comment]

Ç︮ÄÚ¹ÚÅÍ °¨¿°°ú °ü·ÃµÈ metaplastic gastritis¶ó´õ¶óµµ ÀϺο¡¼­ Á¦±ÕÄ¡·á ÈÄ regressionµË´Ï´Ù. µû¶ó¼­ point of no returnÀ̶ó´Â Ç¥ÇöÀ» ´õ ÀÌ»ó »ç¿ëÇÏÁö ¾Ê°í ÀÖ´Ù°í ÇÕ´Ï´Ù. ÀÇÇÐ Àú³Î ÆíÁý½Ç¿¡¼­µµ 'point of no return'À̶ó´Â ¹®±¸¸¦ ¸ðµç article¿¡¼­ Á¦°ÅÇÏ°í ÀÖ´Â ¸ð¾çÀÔ´Ï´Ù.

¿À´Ã SPEM(Spasmoltic Polypeptide Expressing Metaplasia)ÀÌ Àá±ñ ¾ð±ÞµÇ¾ú½À´Ï´Ù. SPEM°ú IM ¸ðµÎ dysplasia¿Í cancerÀÇ precursorÀÔ´Ï´Ù. ³íÁ¡Àº SPEMÀÌ IM¸¦ °¡Á®¿À´Â precursorÀΰ¡Àä, À̹ø review¿¡¼­´Â IM°¡ SPEM¿¡¼­ ¹ß»ýÇÒ ¼öµµ ÀÖ°í de novo·Î ¹ß»ýÇÒ ¼ö ÀÖ´Ù°í ¾ð±ÞµÇ¾î ÀÖ½À´Ï´Ù.

°ú°Å ´ëÇÑ»óºÎÀ§Àå°üÇ︮ÄÚ¹ÚÅÍÇÐȸ Summer Workshop¿¡¼­ ¿¬¼¼´ëÇб³ ³²±âÅà ±³¼ö´Ô²²¼­ ¼Ò°³ÇØ ÁֽŠ¹Ù ÀÖ½À´Ï´Ù. ¿ä¾àÇÏ¿© ¿Å±é´Ï´Ù.

Spasmoltic Polypeptide Expressing Metaplasia (SPEM)
- Marker: TFF2 (trefoil factor2), MUC 6 (Âü°í·Î intestinal metaplasiaÀÇ marker´Â TFF3, MUC2)
- Present in fundic/oxyntic mucosa
- Associated with oxyntic atrophy (parietal cell loss)
- Arises from the base of the glands (antralization / pseudopyloric metaplasia)
- > 90% of cancer resection specimens contain SPEM in adjacent mucosa
- 52% of early gastric cancers stain for TFF2

Âü°í¹®Çå 1: Goldenring & Nam. Prog Mol Biol Transl Sci (2010) Review; Oxyntic atrophy, metaplasia, and gastric cancer - Gastric carcinogenesis involves the loss of parietal cells (oxyntic atrophy) and subsequent replacement of the normal gastric lineages with metaplastic cells. In humans, two metaplastic lineages develop as sequelae of chronic Helicobacter pylori infection: intestinal metaplasia and spasmolytic polypeptide-expressing metaplasia (SPEM). Mouse models of both chronic Helicobacter infection and acute pharmacological oxyntic atrophy have led to the discovery that SPEM arises from transdifferentiation of mature chief cells. The presence of inflammation promotes the expansion of SPEM in mice. Furthermore, studies in Mongolian gerbils as well as increasing evidence from human studies indicate that SPEM likely represents a precursor for the development of intestinal metaplasia. These findings suggest that loss of parietal cells, augmented by chronic inflammation, leads to a cascade of metaplastic events. Identification of specific biomarkers for SPEM and intestinal metaplasia hold promise for providing both early detection of preneoplasia and information on prognostic outcome following curative resection.

Âü°í¹®Çå 2: Nam. Gut (2012) Spasmolytic polypeptide-expressing metaplasia (SPEM) in the gastric oxyntic mucosa does not arise from Lgr5-expressing cells

[ÀÌdz·Ä ±³¼ö´Ô comment]

Metaplasia, dysplasia, carcinoma¿¡ ´ëÇÑ °¡Àå Àß Á¤¸®µÈ ¸®ºäÀÔ´Ï´Ù. Lung cancer, Barrett esophagus, stomach, acinar ductal metaplasia, cervix cancer µîÀÌ ¾ð±ÞµÇ¾î ÀÖ½À´Ï´Ù.

[¹Îº´ÈÆ ±³¼ö´Ô comment]

Colon carcinogenesis


2017-11-28

[Àú³Î] Insights into the Pathophysiology of Esophageal Adenocarcinoma. Gastroenterology 2018

[ÀÌÁØÇà comments]

[ÀÌdz·Ä ±³¼ö´Ô comment]

ÇϺνĵµÀÇ ¹Ù·¿ÀÌ ¹ß»ýÇÏ´Â °úÁ¤¿¡¼­ Ãʱ⿡´Â cardiac typeÀ¸·Î º¯ÇÕ´Ï´Ù. ÀÌ°ÍÀÌ bile°ú pH µîÀÇ microenvironment·Î ÀÎÇÏ¿© ´Ù¸¥ typeÀ¸·Î º¯°æµË´Ï´Ù. SC junction °¡±î¿î °÷ÀÌ intestinal metaplasia°¡ ´õ ¸¹½À´Ï´Ù. Stomach°ú °¡±î¿î °÷Àº oxyntic typeÀ¸·Î ³ª¿À±â ½±½À´Ï´Ù. ¹Ù·¿½Äµµ¿¡¼­ Á¶Á÷°Ë»ç¸¦ ÇÒ ¶§¿¡´Â °¡Àå proximal end¿¡¼­ Á¶Á÷°Ë»ç¸¦ 2°³ ÇØ¾ß ÇÕ´Ï´Ù. ÀÌ»óÀûÀ¸·Î´Â

°ú°Å¿¡´Â ¹Ù·¿½ÄµµÀÇ ¾Ï À§ÇèÀÌ ÀϹÝÀο¡ ºñÇÏ¿© 30¹è¶ó°í À̾߱âÇß¾ú´Âµ¥, ÀüÇâÀû cohort study¸¦ ÅëÇÏ¿© ¸Å³â 860¸í Áß ÇÑ ¸íÀÌ ¾ÏÀÌ µÈ´Ù´Â °ÍÀÌ ¹àÇôÁ³½À´Ï´Ù. ¸Å³â ¾à 0.1%, Áï 100¸íÀ» 10³â ÃßÀû°üÂûÇϸé 1¸í¿¡¼­ ¾ÏÀÌ ¹ß»ýÇÑ´Ù°í ÀÌÇØÇÏ¸é µÇ°Ú½À´Ï´Ù.

[ÀÌÁØÇà comment]

¹Ì±¹ÀÇ data´Â ´ëºÎºÐ long segment ¹Ù·¿À̹ǷΠ¿ì¸®³ª¶ó¿¡¼­´Â ¹Ì±¹ data¿¡ ºñÇÏ¿© ¾Ï¹ß»ý À§ÇèÀº ´Ù¼Ò ³·À» °ÍÀ¸·Î »ý°¢µË´Ï´Ù. 1cm ÀÌÇÏÀÇ ultrashort segment ¹Ù·¿¿¡¼­´Â Á¶Á÷°Ë»ç°¡ ÇÊ¿äÇÏÁö ¾Ê½À´Ï´Ù. 1cm ÀÌÇÏ¿¡¼­´Â ¹Ù·¿À̶ó´Â Áø´Ü¸íÀ» ºÙÀÌÁö ¾Ê¾Æµµ ÁÁÀ» °Í °°½À´Ï´Ù.


2017-11-21

[Àú³Î] Management of Patients With Adenocarcinoma or Squamous Cancer of The Esophagus Gastroenterology 2017

[ÀÌÁØÇà comments]

À¯¸íÇÑ NEJM ¿¬±¸ ÀÌÈÄ T3 ¶Ç´Â N1 À̻󿡼­´Â neoadjuvant CCRT ÈÄ ¼ö¼úÇÏ´Â °ÍÀÌ Ç¥ÁØÀÔ´Ï´Ù. À̺¸´Ù ³·Àº °æ¿ì¿¡µµ neoadjuvant CCRT°¡ Æø³Ð°Ô Àû¿ëµÇ°í ÀÖ½À´Ï´Ù.

NCCN guideline 2016¿¡´Â cT1bN+M0 ¶Ç´Â cT2-T4aN0N+M0¿¡¼­ preop CCRT°¡ ù¹ø°·Î ÃßõµÇ°í ÀÖ½À´Ï´Ù. NCCN °¡À̵å¶óÀÎÀº ƯÁ¤ stage¿¡¼­ ÇÑ ¹æ¹ý¸¸ ±ÇÇÏÁö ¾Ê°í "OR"¸¦ ÀÌ¿ëÇÏ¿© ¿©·¯ ¹æ¹ý Áß ¼±ÅÃÇÒ ¼ö ÀÖ°Ô µÇ¾î ÀÖ½À´Ï´Ù.

[¹Î¾ç¿ø ±³¼ö´Ô comments]

cT2N0M0¿¡ ´ëÇÑ Ä¡·á ¹æħÀº ¾ÆÁ÷ ¸íÈ®È÷ È®¸³µÇ¾î ÀÖÁö ¾Ê½À´Ï´Ù. cT2N0M0ÀÇ clinical stagingÀÌ ±×¸® Á¤È®ÇÏÁö ¾Ê´Ù´Â Á¡µµ ¹®Á¦ÀÔ´Ï´Ù. Understaging µÈ ȯÀÚ°¡ ¸¹±â ¶§¹®ÀÔ´Ï´Ù. Underestimation µÈ ȯÀÚ¿¡¼­´Â CCRT ÈÄ ¼ö¼úÀ» ÇÏ¿´À» ¶§ °á°ú°¡ ´õ ÁÁÀ» ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù.

Á¦5Â÷ »ï¼º¼­¿ïº´¿ø ½Äµµ¾Ï ½ÉÆ÷Áö¾ö ¹Ú¼÷·Ã ±³¼ö´Ô ¹ßÇ¥ ÀÚ·á


2017-11-14

[Àú³Î] Pathophysiology of Eosinophilic Esophagitis Gastroenterology 2017

[ÀÌdz·Ä comment] PPI unresponsive GERD¸¦ ¿¬±¸ÇÏ´Ù°¡ ³ª¿Â Áúº´ÀÌ EoEÀÔ´Ï´Ù. ±×·±µ¥ EoEÀÇ Áø´Ü±âÁØ¿¡ ¸Â´Â ÀϺΠȯÀÚ¿¡¼­ PPI¿¡ response¸¦ º¸ÀÌ´Â »ç¶÷ÀÌ À־ PPI responsive esophageal eosinophilia (PPI-REE)¶ó°í ºÒ·¶½À´Ï´Ù. ÃÖ±Ù¿¡´Â À̵éÀÇ underlying physiology°¡ ÇϳªÀÎ °ÍÀ¸·Î ÀÌÇصǰí ÀÖ½À´Ï´Ù.

[ÀÌÁØÇà Áú¹®] PPI responsive esophageal eosinophilia (PPI-REE)°¡ EoEÀÇ ¾ÆÇüÀ¸·Î °£ÁֵDZ⵵ Çϴµ¥¿ä... ¾î¶² °æ¿ì¿¡ PPI¸¦ ¸ÕÀú ¾²°í, ¾î¶² °æ¿ì¿¡ steroid¸¦ ¸ÕÀú °í·ÁÇմϱî?

[ÀÌdz·Ä ±³¼ö´Ô ´äº¯] ÀÏ´Ü PPI¸¦ 4ÁÖ Á¤µµ ¾²´Â °ÍÀÌ ¿øÄ¢ÀÔ´Ï´Ù.

[ÀÌÁØÇà Áú¹®] ¾î¶² °æ¿ì´Â allergy ³»°ú·Î ÀÇ·ÚÇÏ°í ¾î¶² °æ¿ì´Â ¼ÒÈ­±â³»°ú¿¡¼­ Á÷Á¢ Ä¡·á¸¦ ÇÏ´Â °ÍÀÌ ÁÁÀ»±î¿ä?

[ÀÌdz·Ä ±³¼ö´Ô ´äº¯] Systemic steroid¸¦ Pd·Î »ç¿ëÇÒ ¶§¿¡´Â allergy¿Í ÇùÁøÇÏ´Â °ÍÀÌ ÁÁ½À´Ï´Ù.

[ÀÌÁØÇà comment] EoE¿¡¼­ fibrosisÀÇ ±âÀü¿¡ ´ëÇÏ¿© ºñ±³Àû »ó¼¼È÷ ¾ð±ÞµÇ¾ú½À´Ï´Ù. EoEÀÇ ÁÖµÈ Áõ»óÀº dysphagiaÀε¥, °£È¤ esophageal foreign body ȯÀÚ Áß ÇùÂøºÎÀ§°¡ ¾ø´Â »ç¶÷ÀÌ Àִµ¥ ÀÌ °æ¿ì EoE¸¦ ÀǽÉÇϸé ÁÁ½À´Ï´Ù.

[ÀÌÁØÇà Áú¹® - ½Ã°£ °ü°è·Î ³íÀǸ¦ ¸øÇÏ¿´½À´Ï´Ù. ] Steroid´Â ¾î¶² Á¦ÇüÀ» ¼±ÅÃÇϽôÂÁö¿ä? ´ëÇѼÒÈ­±âÇÐȸÁö(2010;56:285-292)¿¡ ½Ç¸° ¿¬¼¼´ëÇб³ °­³²¼¼ºê¶õ½ºº´¿ø ¹ÚÈ¿Áø ±³¼ö´ÔÀÇ Áõ·Ê¸¦ º¸¸é "Á¤·®½Ä ÈíÀÔ±â(metered dose inhaler, MDI)¸¦ ÀÌ¿ëÇÑ ±¹¼Ò ½ºÅ×·ÎÀ̵å ÈíÀοä¹ý(flucatisone inhaler 125 ug/puff, 1,000 ug/D for 4 weeks)À» ½ÃÇàÇÏ¿´´Ù"°í ±â¼úµÇ¾î ÀÖ½À´Ï´Ù. ¹ÚÈ¿Áø ±³¼ö´ÔÀÇ 2007³â Á¾¼³¿¡´Â inhaler »ç¿ë¹ýÀ» "After shaking the inhaler, take a deep breath. At the point of maximum held inspiration, depress the inhaler and swallow the aerosol with each puff"·Î ¼³¸íÇÏ°í °è½Ê´Ï´Ù. Ã¥¿¡´Â flucatisoneÀÌ ÁÖ·Î ¾ð±ÞµÇ°í ÀÖÁö¸¸ ÇöÀå¿¡¼­´Â budesonideµµ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ½ÇÁ¦·Î´Â ¾î¶»°Ô ÇÏ°í °è½ÅÁö ±Ã±ÝÇÕ´Ï´Ù.

* Âü°í: EndoTODAY È£»ê±¸ ½Äµµ¿°


2017-11-7

[Àú³Î 1] Pathophysiology of Gastroesophageal Reflux Disease (Gastroenterology 2017 - Epub)

[ÀÌdz·Ä ±³¼ö´Ô comment]

BarrettÀÌ À§»ê ¿ª·ù°¡ °¡Àå ÇöÀúÇÑ °ÍÀº ¿©·¯¹ø ¹ßÇ¥µÈ ¹Ù Àִµ¥, Barrett ȯÀÚ¿¡¼­ sensitivity°¡ ³·¾ÆÁø °ÍÀΰ¡´Â °è·®ÀûÀ¸·Î ÀÔÁõµÈ ¹Ù ¾ø½À´Ï´Ù. ÀÌ·ÐÀûÀ¸·Î´Â °­ÇÑ À§»ê ¿ª·ù¸¦ ¹æ¾îÇÏ´Â ±âÀüÀ¸·Î ´Ù¸¥ Á¾·ùÀÇ Á¡¸·À¸·Î º¯È­µÈ °ÍÀ¸·Î ÀÌÇصǰí ÀÖ½À´Ï´Ù.

¸Å¿ì Á¤¸®°¡ Àß µÈ ¸®ºäÀÔ´Ï´Ù. ´Ù¸¸ Obesity, abdominal fatÀÌ GERD ¹ß»ýÀÇ Ãʱ⠱âÀüÀ¸·Î Áß¿äÇÒ °ÍÀ̶ó´Â ºÎºÐÀÌ Àß ´Ù·ç¾îÁöÁö ¾ÊÀº °Í °°½À´Ï´Ù.

[ÀÌÁØÇà comment]

À̹ø review¿¡¼­ ¼Ò°³µÈ ´Ù¼Ò »ý¼ÒÇÑ °³³äÀÎ cascade stomach°ú acid pocketÀº EndoTODAYÀÇ °ü·Ã ¸µÅ©¸¦ Âü°íÇϽñ⠹ٶø´Ï´Ù.


2017-10-31

[Àú³Î 1] Population screening and treatment of Helicobacter pylori infection

NRGH 2017

NRGH 2017

[¹Îº´ÈÆ comment]

Rome 4¿¡¼­ Helicobacter-associated dyspepsia´Â secondary disease·Î Çؼ®µÇ´Â °Í °°½À´Ï´Ù.

[ÀÌdz·Ä comment]

¼¼»ó¿¡ ÁÁÀº Helicobacter´Â ¾ø½À´Ï´Ù. Á¦±Õ ÈÄ À§»êºÐºñ Áõ°¡¿¡ ÀÇÇÑ Áõ»ó ¹ß»ýÀº physiologyÀÇ Á¤»óÈ­·Î ÀÌÇØÇÏ¿©µµ ÁÁÀ» °Í °°½À´Ï´Ù. »êºÐºñ Áõ»óÀº Á¶ÀýÇÒ ¼ö ÀÖ´Â toolÀº ¾î´À Á¤µµ Àֱ⠶§¹®ÀÔ´Ï´Ù. Helicobacter Á¦±ÕÄ¡·á¸¦ °í·ÁÇÏ´Â »óȲ¿¡¼­ GERD³ª ¹Ù·¿ µîÀ» ¾ð±ÞÇÒ ÇÊ¿ä Á¶Â÷ ¾øÀ» °Í °°½À´Ï´Ù.

[ÀÌÁØÇà comment]

1) Ç︮ÄÚ¹ÚÅÍ °¨¿°ÀÇ À¯º´·ü table¿¡ ±Øµ¿À» ´ëÇ¥ÇÏ¿© ÀϺ»°ú Áß±¹ µ¥ÀÌŸ¸¸ ÀÖ°í ¿ì¸®³ª¶ó µ¥ÀÌŸ°¡ ¾ø´Ù´Â Á¡ÀÌ ¾ÈŸ±î¿ü½À´Ï´Ù.

2) ±Ý¹ø ¸®ºä¿¡¼­ 6°³ÀÇ RCT°¡ ÀÖ´Ù´Â tableÀÌ ÀÖÁö¸¸ µ¥ÀÌŸ¸¦ ÅëÇÕÇÏ¿© Á¦½ÃÇÏÁö ¸øÇß½À´Ï´Ù. ¸ÞŸºÐ¼®ÀÌ ¾î·Á¿ï Á¤µµ·Î heterogeneousÇÏ´Ù´Â Á¡ÀÌ ¹®Á¦ÀÔ´Ï´Ù.

3) À§¾Ï ¿¹¹æÀ» À§ÇÏ¿© population ±â¹ÝÀÇ H. pylori Á¦±ÕÄ¡·á¸¦ ÇØ¾ß ÇÑ´Ù´Â °ÍÀº ÀÌÁ¦´Â »ó½Ä¿¡ ¼ÓÇÑ ÀÏÀÔ´Ï´Ù. Á¤ºÎ Á¤Ã¥À¸·Î »ç¾÷À» ÇÏÁö ¸øÇÒ ¸ÁÁ¤ ¾û¶×ÇÑ ±âÁØÀ» µéÀÌ´ë¼­ »è°¨ À§ÇùÀ» ÇÏ´Â °ÍÀº ¾îÀ̾ø´Â ÀÏÀÔ´Ï´Ù. Á¦±ÕÄ¡·á°¡ ÇÊ¿äÇÏ´Ù°í ÀÇ·áÁøÀÌ ÆÇ´ÜÇÑ È¯ÀÚ¿¡ ´ëÇÏ¿© Á¦±ÕÄ¡·á¸¦ ÇÒ ¼ö ÀÖµµ·Ï Á¦µµÀû º¸¿ÏÀ» ÇØ¾ß ÇÒ °ÍÀÔ´Ï´Ù. ¾Æ·¡ °­ÀÇ PPT¿Í µ¿¿µ»óÀ» Âü°íÇϱ⠹ٶø´Ï´Ù.

PPT PDF 2.8M

2017-4-4. MVP symposium


2017-10-24

[Àú³Î 1] Management of GERD Gastroenterology

No clear benefit to escalating the dose beyond 2/day.

PPI´Â heartburn without erosive esophagitis¿¡¼­ 37-61%¸¸ È¿°úÀû

PPI´Â other symptoms without GERD evidence¿¡¼­ "much lower effect"

[ÀÌÁØÇà comment]

H2RA¸¦ ÀÌ¿ëÇÑ step downÀÌ ¾ÆÁ÷µµ È¿°ú°¡ ÀÖÀ»±î¿ä? Àú´Â PPI¸¦ low dose every other day ȤÀº on demand·Î ÃßõÇÏ°í ÀÖ½À´Ï´Ù. ÃÖ±Ù ¸î ³â µ¿¾È step downÀ¸·Î H2RA¸¦ ó¹æÇÑ ±â¾ïÀÌ ¾ø½À´Ï´Ù.

¸®ºä¼­¿¡´Â PPI »ç¿ë¹ý optimizationÀ» Çߴµ¥µµ Áõ»ó È£ÀüÀÌ ¾øÀ¸¸é ´Ù¸¥ ¿øÀÎÀ» ã¾Æº¸µµ·Ï ³ª¿ÍÀÖÁö¸¸, ¿ì¸®³ª¶ó¿¡¼­´Â ¿ö³« °¡Â¥ GERD°¡ ¸¹À¸¹Ç·Î ù PPI¿¡ È¿°ú°¡ ÇöÀúÇÏÁö ¾ÊÀ¸¸é ´Ù¸¥ ¿øÀÎÀ» ã¾Æº¸¾Æ¾ß ÇÒ °Í °°½À´Ï´Ù. ±×³É À¯Çàó·³ ¼ÓÀÌ ºÒÆíÇϸé GERD·Î ºÙÀÌ°í PPI¸¦ ó¹æÇÏ´Â »ç·Ê°¡ ³Ê¹« ¸¹±â ¶§¹®ÀÔ´Ï´Ù.

Manometry¸¦ ÅëÇÏ¿© motor disorder¸¦ °¨º°ÇØ¾ß ÇÑ´Ù°í µÇ¾î ÀÖÁö¸¸, achalasia°¡ Áß¿äÇϱ⠶§¹®¿¡ esophagography¸¦ ÀÌ¿ëÇØ º¼ ¼ö ÀÖÀ» °Í °°½À´Ï´Ù.

173¹ø reference°¡ ÀÌÇõ ±³¼ö´Ô ³í¹®(Am J Gastroenterol 2010)À̾ú½À´Ï´Ù. »ï¼º¼­¿ïº´¿ø°ú °Ç±¹´ëº´¿ø ÇÔ²² ½ÃÇàÇÑ ¿¬±¸¿´´ø ¸ð¾çÀε¥, ÈǸ¢ÇÑ ¿¬±¸ ÃàÇÏÇÕ´Ï´Ù.

[ÀÌdz·Ä ±³¼ö´Ô comment]

[Áú¹®] Heartburn°ú chest painÀ» ¾î¶»°Ô ±¸ºÐÇØ¾ß ÇÒ±î¿ä?
[ÀÌdz·Ä ±³¼ö´Ô comment] Heartburn°ú chest painÀÇ ±¸ºÐ¿¡¼­ À§Ä¡ ±¸ºÐÀÌ °¡Àå Áß¿äÇÕ´Ï´Ù. ¾îµð°¡ ¾ÆÇÂÁö ¤¾îº¸¶ó°í ÇϽʽÿä.

[Áú¹®] Acid exposure timeÀ» 4%¿¡¼­ 6%·Î ¿Ã¸° °ÍÀº?
[ÀÌdz·Ä ±³¼ö´Ô ´äº¯] 30³â Àü¿¡´Â 4%¿´Áö¸¸ ÃÖ±Ù ³í¹®Àº Á¡Â÷ ±× ±âÁØÀÌ ³ô¾ÆÁ®¼­ normal reference°¡ 6%·Î ¹Ù²ï °Í °°½À´Ï´Ù.

4°³ÀÇ groupÀ¸·Î ³ª´©´Â °ÍÀÌ Áß¿äÇÒ °Í °°½À´Ï´Ù. pH impedence °Ë»ç¸¦ ÅëÇÏ¿© 4°³ÀÇ phenotypeÀ¸·Î ³ª´­ ¼ö ÀÖ½À´Ï´Ù. Phenotype 2´Â À§»ê¿¡ ´ëÇÑ ½Äµµ°ú¹Î¼ºÀÔ´Ï´Ù. PPI¸¦ ½á º¸°í Áõ»ó °³¼±ÀÌ ¾øÀ¸¸é pain modulator¸¦ ´õÇØÁÖ¾î¾ß ÇÕ´Ï´Ù. Phenotype 3Àº »ê¿ª·ù´Â ÀÖÀ¸³ª Áõ»óÀº ÀÌ¿Í ¹«°üÇÑ °æ¿ìÀÔ´Ï´Ù. PPI¸¦ ²÷¾îÁÖ¾î¾ß ÇÕ´Ï´Ù. Phenotype 4´Â pain modulator¸¦ ½áº¼ ¼ö ÀÖ½À´Ï´Ù.

2017-10-25. ÀÌdz·Ä ±³¼ö´ÔÀÇ ¼³¸í


2017-10-10

[Àú³Î 1] Approaches for stricture prevention after esophageal endoscopic resection

Abe. GIE 2017

Abe. GIE 2017

ÀÌÁØÇà comment: ¾ÆÁ÷±îÁö´Â triamcinolone local injectionÀ̳ª oral steroid°¡ ÃÖ¼±Àε¥, À̹ø review¿¡¼­´Â local injectionÀÌ °¡Àå ÁÁÀº °Í °°´Ù°í ¾ð±ÞµÇ¾î ÀÖ½À´Ï´Ù. ±×·¯³ª À̹ø ¸®ºä´Â ½Äµµ ESD¸¦ ¸¹ÀÌ ÇÏÁö ¾Ê°í ÀÖ´Â µ¿°æ¾Ï¼¾ÅÍÀÇ ÀÇ°ßÀÔ´Ï´Ù. ±¤¹üÀ§ÇÑ ½Äµµ ESD¸¦ ¸¹ÀÌ ½ÃÇàÇÏ´Â Yamaguchi ¼±»ý´Ô µîÀº circumferential ESD ¿¡¼­´Â oral steroid°¡ local injectionº¸´Ù ´õ ÁÁ´Ù°í ÁÖÀåÇÏ°í ÀÖ½À´Ï´Ù. Àúµµ ÀÌ¿¡ µ¿ÀÇÇÕ´Ï´Ù. (1) µÑÀ» ¸ðµÎ ½ÃÇàÇÏ´Â ÀÌ ´õ µµ¿òÀÌ µÇ´ÂÁö? (2) Çϳª¸¸ ¼±ÅÃÇÑ´Ù¸é local, systemic Áß ¾î´À °ÍÀÌ ´õ ÁÁÀºÁö? (ÀÌ ºÎºÐÀº ÇöÀç JCOG ¿¬±¸°¡ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù) (3) Oral steroinÀÇ ¿ë·®°ú ±â°£Àº? (4) Stomach¿¡¼­´Â µµ¿òÀÌ µÇ´ÂÁö? (Shizoka cancer cancerÀÇ Ono ¼±»ý´Ô ÆÀÀÇ ÈÄÇâÀû ¿¬±¸¿¡¼­ À§¿¡¼­´Â oral steroid°¡ Å©°Ô µµ¿òµÇÁö ¾Ê´Â´Ù°í ³ª¿ÔÁö¸¸, ±×·³¿¡µµ ºÒ±¸ÇÏ°í Ono ¼±»ý´Ô º»Àεµ ¾ÆÁ÷ preventiveÇÏ°Ô oral steroid¸¦ ¾²°í ÀÖ´Ù°í ÇÕ´Ï´Ù. ÆÇ´ÜÀÇ ±Ù°Å°¡ ºÎÁ·ÇÏ´Ù°í º¸´Â °ÍÀÌ ¾ÈÀüÇÒ °Í °°½À´Ï´Ù) µî ¾ÆÁ÷ ºÒ¸íÈ®ÇÑ °ÍÀÌ ¸¹½À´Ï´Ù. Àú´Â °³ÀÎÀûÀ¸·Î oral steroid ´Üµ¶À» ¼±È£Çϴµ¥, ½Äµµ¿¡¼­´Â 8ÁÖ, À§¿¡¼­´Â 4ÁÖ »ç¿ëÇÏ°í ÀÖ½À´Ï´Ù.

¹Î¾ç¿ø ±³¼ö´Ô comment: Long segment circumferential ESD ÈÄ standard 8ÁÖ steroid¸¦ »ç¿ëÇصµ Áß°£(3-4ÁÖ)¿¡ stricture°¡ ¹ß»ýÇÏ´Â ¿¹°¡ ÀÖ½À´Ï´Ù. ÀÌ °æ¿ì temporary stent¸¦ »ç¿ëÇÏ°í ÀÖ½À´Ï´Ù.

* Âü°í: EndoTODAY ½Äµµ ESD ÈÄ ÇùÂø ¿¹¹æ


[Àú³Î 2] Therapeutic endoscopy-related GI bleeding and thromboembolic events in patients using warfarin or direct oral anticoagulants: results from a large nationwide database analysis

DOACÀÌ warfarinº¸´Ù´Â ¾ÈÀüÇÏ°í, heparin bridgingÀº µµ¿òµÇÁö ¾Ê´Â´Ù´Â °á·ÐÀ̾ú½À´Ï´Ù.

High risk procedureÀ» ¿¹»óÇÏ´Â »óȲ¿¡¼­ ÀϽÃÀûÀ¸·Î warfarinÀ» DOACÀ¸·Î ¹Ù²ã¼­ »ç¿ëÇÏ´Â °ÍÀ» °í·ÁÇÒ ¼ö ÀÖ´Ù°í ¾ð±ÞµÇ¾î ÀÖ½À´Ï´Ù. ½ÇÁ¦ ½ÉÀå³»°ú¿¡ ÀÇ·ÚÇغ¸¸é °¡²û ±×¿Í °°Àº ÃßõÀ» ÇØ ÁÖ´Â °æ¿ì°¡ ÀÖ½À´Ï´Ù.

ÀÌÁØÇà comment: Warfarin »ç¿ë ȯÀÚ¿¡¼­µµ »çÀü¿¡ ȯÀÚ¿¡¼­ ÃâÇ÷ À§Ç輺À» ¼³¸íÇÑ ÈÄ À§³»½Ã°æÀ̳ª ´ëÀå³»½Ã°æ¿¡¼­ Á¶Á÷°Ë»ç´Â ½ÃÇàÇÒ ¼ö ÀÖ½À´Ï´Ù.


2017-9-26 - ³»½Ã°æ½Ç ºÐ¾ßº° °ËÅä - ¹ßÇ¥ÀÚ: ºÐ¾ßº° ´ã´ç ±³¼ö´Ô (powerpoint·Î ¸¸µé ÇÊ¿ä´Â ¾ø½À´Ï´Ù. ±×³É ¸»·Î ¹ßÇ¥ÇØ ÁÖ½Ã¸é µË´Ï´Ù)


2017-9-19

[Àú³Î] Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan

[ÀÌÁØÇà comment] ¸Å¿ì ÀϺ»ÀûÀÎ ³í¹®ÀÔ´Ï´Ù. (1) ±×µ¿¾È barium study°¡ screeningÀ¸·Î ÁÁ´Ù°í ÁÖÀåÇÏ´õ´Ï, À̹ø ³í¹®¿¡¼­´Â "almost no change after the start of screening with barium studies"¶ó°í ¾²°í ÀÖ½À´Ï´Ù. Ç︮ÄÚ¹ÚÅÍ Á¦±ÕÄ¡·á°¡ ÁÁ´Ù´Â ÁÖÀåÀ» À§ÇÏ¿© º° ¼³¸íµµ ¾øÀÌ barium studyÀÇ È¿°ú¸¦ ¾ø´ø ÀÏ·Î ÇÏ°í ÀÖ½À´Ï´Ù. (2) Á¦±ÕÄ¡·á¸¦ ½ÃÀÛÇÏÀÚ¸¶ÀÚ ¾ÏÀÌ ÁÙ¾ú´Ù´Â °Í¿¡ ´ëÇÑ ÇÕ¸®Àû ¼³¸í ¾øÀÌ "Á¦±ÕÄ¡·á¸¦ Çß´õ´Ï ¾Ï »ç¸Á·üÀÌ ÁÙ¾ú´Ù"°í ¸»ÇÏ°í ÀÖ½À´Ï´Ù. ´ë¼¼¿¡ µû¶ó Àº±Ù½½Â½ ÀÚ½ÅÀÇ ÀÔÀåÀ» ¹Ù²Ù°í, À̸¦ À§ÇÏ¿© µ¥ÀÌŸ¸¦ ÀÚÀÇÀûÀ¸·Î Çؼ®ÇÏ´Â ¸ð½ÀÀÔ´Ï´Ù. ÀϺ»¿¡¼­ (1) 2013³â ³»½Ã°æ °Ë»ç¿¡¼­ H. pylori gastritis·Î È®ÀÎµÈ »ç¶÷ (ÀÌ·¯ÇÑ Á¶°ÇÀÇ Àǹ̴ ³»½Ã°æÀ¸·Î H. pylori¸¦ È®ÀÎÇ϶ó´Â °ÍÀÌ ¾Æ´Ï°í À§¾ÏÀÌ ¾Æ´Ï¶ó´Â °ÍÀ» ³»½Ã°æÀ¸·Î È®ÀÎÇ϶ó´Â °ÍÀÔ´Ï´Ù)¿¡ ´ëÇÑ Á¦±ÕÄ¡·á°¡ º¸Çè±Þ¿©µÇ±â ½ÃÀÛÇÏ¿´´Ù, (2) ±× ÀÌÈÄ Á¦±ÕÄ¡·á ó¹æÀÌ ¾à 2¹è Áõ°¡ÇÏ¿´´Ù Á¤µµ·Î ÀÌ¿ô ³ª¶óÀÇ ÇöȲÀ» º¸¿©ÁÖ´Â º¸°í¼­·Î ÀÌÇØÇÏ¸é µÇ°Ú½À´Ï´Ù.

ÇÑ ¸¶µð ´õ... À̹ø¿¡ ÀϺ» Ç︮ÄÚ¹ÚÅÍ Á¦±ÕÄ¡·á ÇöȲÀ» °ËÅäÇϸ鼭 ÀϺ»¿¡¼­ °¡Àå ¸¹ÀÌ »ç¿ëµÇ°í Àִ ó¹æÀ» ¾Ë°Ô µÇ¾ú½À´Ï´Ù. ÀÌ ¾à Àú ¾à µû·Î ó¹æÇÏÁö ¾Ê°í set·Î µÇ¾î ÀÖ´Â ¾à(treatment pack formulation)À» »ç¿ëÇÑ´Ù°í ÇÕ´Ï´Ù. »óÇ°¸íÀ¸·Î Lansap°ú Rabecure¶ó°í ÇÕ´Ï´Ù.


2017-9-12

[Àú³Î]

1. A Comparison of the Rate of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin - NOACÀÌ Ã³À½ »ý°¢Çß´ø °Í¸¸Å­ GI bleeding risk°¡ ³ôÁö ¾Ê´Ù´Â º¸°íÀÔ´Ï´Ù. Warfarin »ç¿ëÀÚ bleedingÀÇ °æ¿ì INRÀÌ ¾î´À ¹üÀ§¿´´ÂÁö ±Ã±ÝÇÕ´Ï´Ù.

ÀÌÁØÇà comment 1) 2017³â 7¿ù 10ÀÏ ¿ù¿äÁý´ãȸ¿¡¼­ ÀÌ ÁÖÁ¦¿¡ ´ëÇÑ ¸ÞŸ ºÐ¼® (Clin Gastroenterol Hepatol 2017)À» °ËÅäÇÑ ¹Ù ÀÖ½À´Ï´Ù (40 articles, 43 trials, 166,289 patients randomized). ¸ÞŸºÐ¼® °á°ú¿Í À̹ø ¿¬±¸ °á°úÀÇ Â÷ÀÌÁ¡¿¡ ´ëÇÏ¿© Àá½Ã »ý°¢ÇØ º¸¾Ò½À´Ï´Ù.

ÇÙ½É µµÇ¥ÀÔ´Ï´Ù. ÀüüÀûÀ¸·Î º¼ ¶§ major GI bleedingÀº NOAC¿¡¼­ 1.5%, conventional anticoagulation¿¡¼­ 1.3%·Î º°´Ù¸¥ Â÷ÀÌ°¡ ¾ø¾ú½À´Ï´Ù.

¾àÁ¦º°·Î »ìÆ캸¾ÒÀ» ¶§, dabigatranÀº major GI bleedingÀÌ warfarinº¸´Ù Á¶±Ý ¸¹¾Ò½À´Ï´Ù.

¾àÁ¦º°·Î »ìÆ캸¾ÒÀ» ¶§, ribaroxabanµµ major GI bleedingÀÌ warfarinº¸´Ù Á¶±Ý ¸¹¾Ò½À´Ï´Ù.

¾àÁ¦º°·Î »ìÆ캸¾ÒÀ» ¶§, apixabanÀº warfarin°ú ºñ½ÁÇß½À´Ï´Ù.

¾àÁ¦º°·Î »ìÆ캸¾ÒÀ» ¶§, edoxabanµµ warfarin°ú ºñ½ÁÇß½À´Ï´Ù.

ÀÌÁØÇà comment 2) Warfarin »ç¿ëÀÚ¿¡¼­ INRÀÌ Àß Á¶ÀýµÇ¸é ÃâÇ÷·üÀÌ ³·Àº ¹Ý¸é INRÀÌ ³ôÀº °æ¿ì ÃâÇ÷ÀÌ ¸¹½À´Ï´Ù. ÇÑ ¿¬±¸¸¦ º¸¸é warfarin »ç¿ëÀÚÀÇ ÃâÇ÷ À§Çè ÀÎÀÚ´Â °í·É, INR »ó½Â, À§Àå°ü ÃâÇ÷ÀÇ °ú°Å·Â, °£°æº¯ÁõÀ̾ú½À´Ï´Ù (Biomed Res Int 2014).

Biomed Res Int 2014

[¹Î¾ç¿ø ±³¼ö´Ô comment]

Randomized trial¿¡¼­ NOACÀÌ warfarinº¸´Ù ÃâÇ÷À§ÇèÀÌ ³ô´Ù°í ³ª¿Â °á°ú°¡ real world practice¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â °Í °°½À´Ï´Ù (°íÀ§Çè ȯÀÚ¿¡¼­´Â NOACÀ» ÇÇÇѴٰųª, ´Ù¸¥ ¿¹¹æÁ¶Ä¡¸¦ °­±¸Çϰųª µî). ±× °á°ú real world¿¡¼­´Â NOACº¸´Ù warfarinÀÇ ÃâÇ÷·üÀÌ ´õ ³ô¾ÆÁø °Í ¾Æ´Ñ°¡ ÃßÁ¤µË´Ï´Ù. ƯÈ÷ Àӻ󿬱¸°¡ ¾Æ´Ñ real world¿¡¼­´Â INRÀÌ ºÎÀûÀýÇÏ°Ô ³ô¾ÆÁø ȯÀÚ°¡ ÀûÁö ¾Ê´Ù´Â °Íµµ ¿µÇâÀ» ¹ÌÄ¥ °Í °°½À´Ï´Ù.

[ÀÌÁØÇà comment]

ÀûÀýÇÑ ÁöÀûÀÔ´Ï´Ù. ¿¹ÃøÀÌ Á¤È®ÇÏ¸é ¿¹Ãø´ë·Î µÇÁö ¾Ê½À´Ï´Ù. ÃâÇ÷ÀÌ ³ôÀ» °ÍÀ¸·Î ¿¹»óµÇ¸é ´Ùµé ÃâÇ÷À» ÇÇÇÏ´Â ³ë·ÂÀ» Çϱ⠶§¹®ÀÔ´Ï´Ù. Randomized trial°ú real world clinical review¸¦ Àß ±¸ºÐÇÏ¿© °á°úÇؼ®À» ÇØ¾ß ÇÕ´Ï´Ù.


2. ACG and CAG Clinical Guideline: Management of Dyspepsia

Helicobacter pylori test and test -- PPI -- TCA or prokinetics -- psychotherapy ¼ø¼­·Î ÃßõµÇ¾î ÀÖ½À´Ï´Ù.

[¹Î¾ç¿ø ±³¼ö´Ô comment]

60¼¼ ÀÌ»óÀ̸é À§³»½Ã°æÀ» Ç϶ó°í Çß½À´Ï´Ù (conditional recommendation, very low quality evidence). ±×·¯³ª ¿ì¸®³ª¶ó¿¡¼­´Â ÈξÀ ÀþÀº ³ªÀÌ¿¡¼­ºÎÅÍ ³»½Ã°æÀÌ ÇÊ¿äÇÕ´Ï´Ù. À§¾ÏÀÇ À¯º´·ü°ú ³»½Ã°æ °Ë»çÀÇ °¡°Ý µîÀ» °í·ÁÇÏ¿© Áö¿ª¸¶´Ù ÁöħÀÌ ´Ù¸¦ ¼ö ÀÖ½À´Ï´Ù.

[ÀÌdz·Ä ±³¼ö´Ô comment]

Evidence-based guidelineÀº ÇöÀçÀÇ ÇüÅ°¡ µÉ ¼ö ¹Û¿¡ ¾ø½À´Ï´Ù. Expert opinionÀÌ ÃæºÐÈ÷ ¹Ý¿µµÇ¸é ÀÌ¿Í´Â Á¶±Ý ´Ù¸¥ ¸ð½ÀÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. Helicobacter¿¡ ´ëÇÏ¿© °ú°Å¿¡´Â °ü·ÃÀÌ ¾ø´Ù´Â ¿¬±¸°¡ ¸¹¾Ò´Âµ¥, gastric acid secretion µîÀ» Àß °í·ÁÇÑ´Ù¸é Helicobacter´Â ¾î´À Á¤µµ °ü·ÃµÇ¾î ÀÖ´Â °Í °°½À´Ï´Ù. Kyoto consensus¿¡¼­´Â Helicobacter-associated dyspepsia°¡ functional dyspepsia Ä«Å×°í¸®·Î Æ÷ÇԵǾî ÀÖ½À´Ï´Ù¸¸, ¿©·¯ Á¶°ÇÀ» Àß »ìÆì¼­ ÀûÀýÇÏ°Ô ÀÓ»ó¿¡ Àû¿ëÇϸé ÁÁÀ» °Í °°½À´Ï´Ù.

Kyoto consensus

Kyoto consensus


2017-9-5

[Àú³Î] G-POEM

[ÀÌdz·Ä ±³¼ö´Ô comment] º´Å»ý¸®°¡ ¸íÈ®ÇÏÁö ¾ÊÀº Áúȯ¿¡¼­ pylorus¸¸ ¿­¾îÁÖ¾ú±â ¶§¹®¿¡ response rate°¡ »ý°¢º¸´Ù ³·°Ô ³ª¿Â °Í°°½À´Ï´Ù. Botox Ä¡·áÀÇ È¿°úµµ º°·Î ÁÁÁö ¾ÊÀº »óȲÀ̾úÀ¸¹Ç·Î G-POEMµµ ÇÑ°è°¡ ÀÖÀ» °ÍÀ¸·Î »ý°¢µË´Ï´Ù. Metoclopramide, domperidone, macrolide (tachyphylaxisÀÌ ¹®Á¦ÀÓ) µî ¾àÁ¦ÀÇ È¿°ú°¡ Á¦ÇÑÀûÀÌ°í, electric pacingÀÌ È¿°úÀûÀ̶ó°í ¾Ë·ÁÁ³À¸³ª ÇöÀç´Â °è¼Ó negative data°¡ ³ª¿À°í ÀÖ½À´Ï´Ù. Gastrojejunostomy´Â È¿°ú°¡ ¾ø°í total gastrectomy°¡ µµ¿òµÈ´Ù´Â ¾ÆÁÖ ¿¾³¯ µ¥ÀÌŸ°¡ ÀÖ½À´Ï´Ù. ÇöÀç´Â º´Å»ý¸®¿¡ ´ëÇÑ ±Ô¸íÀÌ ¸íÈ®ÇÏÁö ¾Ê¾Æ¼­ Á» ´õ ÁöÄѺÁ¾ß ÇÒ °Í °°½À´Ï´Ù. Delayed emptying¿¡ ´õÇÏ¿© Áõ»ó µî supporting evidence°¡ ÀÖ´Â °æ¿ì¸¸ gastroparesis·Î ºÎ¸¦ ¼ö ÀÖÀ» °Í °°½À´Ï´Ù. Delayed emptying ´Üµ¶¸¸À¸·Î gastroparesis¶ó°í ºÎ¸£¸é °ï¶õÇÒ °Í °°½À´Ï´Ù.


2017-8-29

[Review article] Magnification narrow-band imaging for the diagnosis of early gastric cancer: a review of the Japanese literature for the Western endoscopist

PPT PDF 1.2M (GIE review, À̼ÒÁ¤)

[Áõ·Ê] Cowden disease

PPT PDF 2.3M

[Áõ·Ê] »óºÎ½Äµµ ¼±¾Ï -- CCRT ÈÄ no residual tumor


2017-8-22

[Àú³Î 1] The use of selective serotonin receptor inhibitors (SSRIs) is not associated with increased risk of endoscopy-refractory bleeding, rebleeding or mortality in peptic ulcer bleeding. - Á¦¸ñ°ú ¿ä¾àÀÇ introduction ºÎºÐ¿¡ °ÅÀÇ ¸ðµç informationÀÌ ÀÖ½À´Ï´Ù.

SSRI¿¡¼­ platlet¿¡¼­ serotonin reuptake transporter¸¦ ¾ïÁ¦ÇÏ¿© »óºÎÀ§Àå°üÃâÇ÷ÀÌ 1.55¹è ¸¹´Ù°í º¸°íµÈ ¹Ù ÀÖ½À´Ï´Ù.

[ÀÌÁØÇà comment] ³î¶ó¿î Á¡Àº nataional database¿¡ ±Ù°ÅÇÑ °á·ÐÀ̶ó´Â Á¡À̾ú½À´Ï´Ù. ´ë»ó ȯÀÚ°¡ 13,000¸í Á¤µµ¿´½À´Ï´Ù. DenmarkÀÇ ÀÇ·á ½Ã½ºÅÛÀÌ ¾î¶°ÇÑÁö °ËÅäÇØ º¼ ÇÊ¿ä°¡ ÀÖÀ» °Í °°³×¿ä.

[Àú³Î 2] Superficial esophageal mucosal afferent nerves may contribute to reflux hypersensitivity in non-erosive reflux disease - Èï¹Ì·Î¿î °á·ÐÀÔ´Ï´Ù. "Proximal and distal esophageal mucosa of patients with NERD have more superficial afferent nerves compared with controls or patients with ERD or BE."

ÀúÀÚµéÀº IntroductionÀ» ÅëÇÏ¿© °ú°Å¿¡ ¾ð±ÞµÇ´ø DIS(dilated intercellular space)´Â GERDÀÇ ¿øÀÎÀ̶ó±âº¸´Ù´Â ¿°Áõ¿¡ µû¸¥ ºñƯÀÌÀû º¯È­ÀÎ °ÍÀ¸·Î ¾ð±ÞÇÏ¿´½À´Ï´Ù. Nociceptive sensory marker (labeled antibody against calcitonin gene related peptide (CGRP))¸¦ ÀÌ¿ëÇÏ¿© ½Äµµ Á¶Á÷ °ËüÀÇ innervationÀÇ À§Ä¡¸¦ °Ë»çÇÏ¿´½À´Ï´Ù.

°á°ú: The distribution of CGRP-positive nerves did not differ significantly between the distal esophageal mucosa of controls (median 25.5 cell layers to surface; interquartile range, 21.4-28.8) vs patients with ERD (median 23 cell layers to surface; interquartile range, 16-27.5) or patients with BE (median 21.5 cell layers to surface; interquartile range, 16.1-27.5). However, CGRP-positive nerves were significantly more superficial in mucosa from patients with NERD-both distal (median 9.5 cell layers to surface; interquartile range, 1.5-13.3; P<.0001 vs ERD, BE, and controls) and proximal (median 5.0 cell layers to surface; interquartile range, 2.5-9.3 vs median 10.4 cell layers to surface; interquartile range, 8.0-16.9; P=.0098 vs controls).

Áõ·Ê

Comment: ´ëÀå³»½Ã°æÀ» ÁغñÇÏ¿© °Ë»çÇÏ´ø Áß ´ëÀå¾ÏÀÇ obstructionÀ¸·Î ÀÎÇÏ¿© proximalÂÊÀ» °Ë»çÇÏÁö ¸øÇÑ È¯ÀÚ¿¡¼­ °Ë»ç code¸¦ Á÷Àå°æÀ¸·Î º¯°æÇÏ´Â °ÍÀÌ ¿ÇÀ»Áö ¹®ÀÇ°¡ ÀÖ¾ú½À´Ï´Ù. Á¦ »ý°¢À¸·Î´Â ´ëÀå³»½Ã°æÀ» ÀǵµÇÏ¿´´ø ȯÀÚ¿¡¼­ obstructionÀ¸·Î »ó¹æÀ» º¸Áö ¸øÇÑ °ÍÀº ÀǵµÇÏ¿´´ø °Ë»ç°¡ ´Ù µÈ °ÍÀ¸·Î º¸´Â °ÍÀÌ ¸ÂÀ» °Í °°½À´Ï´Ù.


2017-8-8

[Review the review] 2017³â Gastroenterology review (Vaezi MF. Gastroenterology 2017 - PDF)

PPI ºÎÀÛ¿ë¿¡ ´ëÇÏ¿© ÀÇ·á°è¿Í ȯÀÚ »çȸ¿¡¼­ ¿ì·ÁÀÇ ¸ñ¼Ò¸®°¡ ³ô½À´Ï´Ù. ¾Æ·¡¿Í °°Àº ¿Â°® Àå±âÀÇ ¿Â°® ºÎÀÛ¿ëÀÌ ÀÇÇÐ ¹®Çå¿¡ ȤÀº ¾ð·Ð¿¡¼­ °Å·ÐµÇ°í ÀÖ½À´Ï´Ù.

±×·¯³ª Àΰú°ü°è¸¦ ÀÔÁõÇϱâ¶õ ½¬¿î ÀÏÀÌ ¾Æ´Õ´Ï´Ù. Hill criteria¸¦ ¸¸Á·ÇÏÁö °ËÅäÇØ¾ß ÇÕ´Ï´Ù.

Áö±Ý±îÁöÀÇ ÀÚ·á¿¡ ÀÇÇÏ¸é °Å·ÐµÇ´Â ºÎÀÛ¿ëÀÇ relative risk´Â ±×¸® ³ôÁö ¾Ê½À´Ï´Ù. °üÂû¿¬±¸ÀÇ bias¸¦ °í·ÁÇÒ ¶§ º¸Åë 3 ÀÌ»óÀº µÇ¾î¾ß Àǹ̰¡ ÀÖ½À´Ï´Ù. ÀÌ´Â Á¤È®È÷ ÃøÁ¤Çϱ⠾î·Á¿î confounding factor°¡ ¸¹±â ¶§¹®ÀÔ´Ï´Ù.

¾Æ·¡¿Í °°Àº ÁöÀûÀº ¸Å¿ì ÀûÀýÇÕ´Ï´Ù.

"Many recent publications have, however, pointed out that a great number of patients are receiving PPIs unnecessarily for conditions or symptoms for which they would not have been expected to provide benefit. Furthermore, many patients who are on PPI treatment for appropriate indications are receiving excessively high daily doses. It is a sound adage of medical practice that all drugs should be given in the lowest effective dose and for the shortest possible time. This is as true for PPIs as it is for any other drug class."

À̹ø ¸®ºä´Â ³Ê¹«³ª Ÿ´çÇÏ°Ôµµ ¾Æ·¡¿Í °°Àº °á·ÐÀ» ³»°í ÀÖ½À´Ï´Ù.

"Much of the current evidence linking PPI use to serious long-term adverse consequences is weak and insubstantial. It should not deter prescribers from using appropriate doses of PPIs for appropriate indications."


[¹Îº´ÈÆ ±³¼ö´Ô ªÀº Ư°­] Á¶±âÀ§¾Ï ³»½Ã°æ Ä¡·á ÀûÀÀÁõÀÇ ÃֽŠ°æÇâ

PPT PDF 0.9M

ºÐÈ­Çü Á¶±âÀ§¾Ï, 500 um ÀÌÇÏÀÇ SM1 cancerµµ Àç¹ßÀ§ÇèÀÌ ÀÖ½À´Ï´Ù. ÇöÀçÀÇ expanded criteria¸¦ Á¶±Ý Ãà¼ÒÇØ¾ß ÇÏÁö ¾ÊÀ»±î »ý°¢µË´Ï´Ù. ÀÌÀ¯´Â ¼¼ °¡ÁöÀÔ´Ï´Ù.

(1) Depth of invasion ÃøÁ¤ ±âÁØÀÌ ºÒ¸íÈ®ÇÕ´Ï´Ù.

(2) Surgical case¿¡¼­ expanded criteria¿¡ ÇØ´çÇϴ ȯÀÚÀÇ ¸²ÇÁÀý ÀüÀÌ°¡ È®ÀεǾú½À´Ï´Ù.

(3) Extragastric recurrence´Â ºÐ¸í Á¸ÀçÇÕ´Ï´Ù.

¹ÌºÐÈ­Çü Á¶±âÀ§¾Ï

Surgical data¿¡¼­´Â ¸²ÇÁÀý ÀüÀÌ°¡ ÀÖÀ¸³ª ESD series¿¡¼­ Àç¹ßÀº ¾ø¾ú½À´Ï´Ù. Å©±â°¡ ÀÛ´Ù¸é (<=1cm) ESD¸¦ ½ÃµµÇÒ ¼ö ÀÖÁö ¾ÊÀ»±î »ý°¢µË´Ï´Ù.


2017-7-25

3Â÷ box simulator training course (ÀÚ¿øÀÚ) : 7¿ù 26ÀÏ (¼ö) ÇãÂù¹Ì, ¼ÛÁÖÇý

±èÅÂÁØ ±³¼ö´Ô: ´ëÀå³»½Ã°æ box simulator ÈÆ·Ã ÁøÇà »óȲ

2018³âºÎÅÍ ³»°ú ½Ç½ÀÇлý ´ë»óÀÇ box simulator ÈÆ·ÃÀ» ÀÇ°ú´ëÇп¡ Á¦¾ÈÇÏ¿´½À´Ï´Ù.

¹Î¾ç¿ø ±³¼ö´Ô: Fecal transplantation Áغñ »óȲ

8¿ù 26ÀÏ (÷Ï) ESD hands-on course (»ï¼º¼­¿ïº´¿ø) Áغñ »óȲ

[Àú³Î] No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer's Disease.

¹è°æ: PPI°¡ beta-amyloid¸¦ Áõ°¡½Ãų ¼ö Àֱ⠶§¹®¿¡ (ƯÈ÷ lansoprazole) Alzheimer¿¡ ´ëÇÑ ¿ì·Á°¡ ÀÖ¾ú½À´Ï´Ù.

±×·¯³ª °á·ÐÀº negative ¿´½À´Ï´Ù.


Âü°í: 2017³â Gastroenterology review (Vaezi MF. Gastroenterology 2017 - PDF)

PPI ºÎÀÛ¿ë¿¡ ´ëÇÏ¿© ÀÇ·á°è¿Í ȯÀÚ »çȸ¿¡¼­ ¿ì·ÁÀÇ ¸ñ¼Ò¸®°¡ ³ô½À´Ï´Ù. ¾Æ·¡¿Í °°Àº ¿Â°® Àå±âÀÇ ¿Â°® ºÎÀÛ¿ëÀÌ ÀÇÇÐ ¹®Çå¿¡ ȤÀº ¾ð·Ð¿¡¼­ °Å·ÐµÇ°í ÀÖ½À´Ï´Ù.

±×·¯³ª Àΰú°ü°è¸¦ ÀÔÁõÇϱâ¶õ ½¬¿î ÀÏÀÌ ¾Æ´Õ´Ï´Ù. Hill criteria¸¦ ¸¸Á·ÇÏÁö °ËÅäÇØ¾ß ÇÕ´Ï´Ù.

Áö±Ý±îÁöÀÇ ÀÚ·á¿¡ ÀÇÇÏ¸é °Å·ÐµÇ´Â ºÎÀÛ¿ëÀÇ relative risk´Â ±×¸® ³ôÁö ¾Ê½À´Ï´Ù. °üÂû¿¬±¸ÀÇ bias¸¦ °í·ÁÇÒ ¶§ º¸Åë 3 ÀÌ»óÀº µÇ¾î¾ß Àǹ̰¡ ÀÖ½À´Ï´Ù. ÀÌ´Â Á¤È®È÷ ÃøÁ¤Çϱ⠾î·Á¿î confounding factor°¡ ¸¹±â ¶§¹®ÀÔ´Ï´Ù.

¾Æ·¡¿Í °°Àº ÁöÀûÀº ¸Å¿ì ÀûÀýÇÕ´Ï´Ù.

"Many recent publications have, however, pointed out that a great number of patients are receiving PPIs unnecessarily for conditions or symptoms for which they would not have been expected to provide benefit. Furthermore, many patients who are on PPI treatment for appropriate indications are receiving excessively high daily doses. It is a sound adage of medical practice that all drugs should be given in the lowest effective dose and for the shortest possible time. This is as true for PPIs as it is for any other drug class."

À̹ø ¸®ºä´Â ³Ê¹«³ª Ÿ´çÇÏ°Ôµµ ¾Æ·¡¿Í °°Àº °á·ÐÀ» ³»°í ÀÖ½À´Ï´Ù.

"Much of the current evidence linking PPI use to serious long-term adverse consequences is weak and insubstantial. It should not deter prescribers from using appropriate doses of PPIs for appropriate indications."

InfectionÀº È®½ÇÈ÷ Áõ°¡µË´Ï´Ù. Cirrhosis ȯÀÚÀÇ SBP, claim data·Î fracture¿Í ¿¬°ü¼ºÀÌ ÀÖ´Ù°í µÇ¾î ÀÖ½À´Ï´Ù.


2017-7-18.

3Â÷ box simulator training course (ÀÚ¿øÀÚ) : 7¿ù 25ÀÏ (È­) - 7¿ù 26ÀÏ (¼ö)

±èÅÂÁØ ±³¼ö´Ô: ´ëÀå³»½Ã°æ box simulator ÈÆ·ÃÀ» À§ÇÑ °èȹÀ» Àâ¾ÆÁÖ¼¼¿ä.

[Àú³Î]

¿äÁò À¯ÇàÀÎ indirect evidence, mixed meta-analysisÀÔ´Ï´Ù.

1) First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis

2) Efficacy of Helicobacter pylori eradication therapies in Korea: A systematic review and network meta-analysis.

[ÀÌÁØÇà Áú¹®] Maastricht V Florence Consensus Report¸¦ ¹ßÇ¥ÇÑ Malfertheiner¹Ú»ç´Â "Sequential is out"¶ó°í ÁÖÀåÇÑ ¹Ù ÀÖ½À´Ï´Ù. ¿Ö ±×ºÐÀº ±×·¸°Ô °ú°ÝÇÑ ÁÖÀåÀ» Çϼ̽À´Ï±î?

[ÀÌÇõ ±³¼ö´Ô ´äº¯] ¾ÆÁ÷±îÁö Sequential is out ¶ó°í ºÎ¸¦¸¸ÇÑ ºÎÁ¤ÀûÀÎ data°¡ ÀÖ´Â °ÍÀº ¾Æ´Õ´Ï´Ù. ¿ÀÈ÷·Á ±àÀûÀûÀÎ ÂÊÀÇ ÀÚ·á°¡ ¸¹½À´Ï´Ù.

* Âü°í: EndoTODAY Current status of H pylori eradication therapies in Korea (±èÀçÁØ ±³¼ö´Ô)


2017-7-11.

[Áõ·Ê] Sclerosing mesenteritis

2017³â IDEN¿¡¼­ ¼º¸ðº´¿øÀÇ sclerosing mesenteritis Áõ·Ê¸¦ ¼Ò°³ÇÑ ¹Ù ÀÖ½À´Ï´Ù.

Autoimmune pancreatitis·Î Ä¡·á¹ÞÀº º´·ÂÀÌ ÀÖ´Â 77¼¼ ³²ÀÚ°¡ hematochezia·Î ³»¿ø. CT¿¡¼­ mesenteric root ÁÖº¯ÀÇ soft tissue mass¿Í mesenteric lymphadenopathies°¡ ¹ß°ßµÇ¾ú°í, serum IgG4°¡ Á¤»ó »óÇÑÄ¡ÀÇ 2¹èÀÎ 266 mg/dL±îÁö »ó½ÂµÇ¾î ÀÖ¾úÀ¸¸ç, º¹°­°æÀ¸·Î ¸²ÇÁÀý Á¶Á÷°Ë»ç¿¡¼­ "lymphoplasmocytic infiltration, moderate to severe fibrosis with many IgG4 positive plasma cells ¼Ò°ßÀÌ ³ª¿Í IgG4-relates sclerosing mesenteritis (SM)·Î Áø´ÜÇÏ°í steroid »ç¿ëÀ¸·Î È£ÀüµÊ. SM was recently reported to be closely related to IgG4-realted disease, a systemic syndrome characterized by mass-like lesions in various organs infiltrated by IgG4-positive plasma cells and high serum IgG4 concentrations.

µå¹® ÁúȯÀÎÁö¶ó ¼º¸ðº´¿ø Áõ·Ê¸¦ õõÈ÷ ´Ù½Ã »ìÆ캸¾Ò°í ÀÌ¿¡ ´ëÇÑ ¸®ºä¸¦ ÇÏ¿´½À´Ï´Ù (Àü°øÀÇ ±èÁ¤À± ¼±»ý´Ô).

°¡Àå Áß¿äÇÑ ½½¶óÀ̵帳´Ï´Ù. IgG4-realted disease°¡ ¾Ë·ÁÁö±â Àü±îÁö °¢ Àå±âº° Ư¼º¿¡ µû¶ó º°µµÀÇ Áø´Ü¸íÀÌ ÀÖ¾ú½À´Ï´Ù. ÀúÈñ ¼ÒÈ­±â³»°ú Àǻ翡°Ô °ü½ÉÀÖ´Â ¿µ¿ªÀº autoimmune pancreatitis, sclerosing mesenteritis (¸®ºä), retroperitoneal fibrosis µîÀÔ´Ï´Ù.

[Àú³Î]

1) Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial

»ó½ÄÀûÀ¸·Î ¾Ë°í ÀÖ´Â ¹Ù·Î ±× ³»¿ëÀ» Columbian trial¿¡¼­ ´Ù½Ã Çѹø º¸¿©ÁØ ³í¹®ÀÔ´Ï´Ù. Intestinal metaplasia´Â point of no returnÀ̶ó°í »ý°¢ÇÏ´Â ºÐµéÀÌ ¸¹Áö¸¸ »ç½Ç intestinal metaplasia°¡ Àִ ȯÀÚµµ Á¦±ÕÄ¡·á¸¦ ÇÏ¸é ´Ù¼Ò ÁÁ¾ÆÁø´Ù´Â °ÍÀÔ´Ï´Ù. Ç︮ÄÚ¹ÚÅÍ Á¦±ÕÄ¡·áÀÇ µæ°ú ½ÇÀ» µûÁ®º¼ ¶§, °í·ÉÀ̰ųª intestinal metaplasia°¡ ÀÖ´Ù´Â ÀÌÀ¯·Î Ä¡·á±º¿¡¼­ »¬ ÀÌÀ¯°¡ ¾ø´Ù°í »ý°¢ÇÕ´Ï´Ù. ÇöÀç ¿ì¸®³ª¶ó Á¤ºÎÀÇ ¹æħÀº À§¾Ï Á¶±âÁø´Ü¿¡¸¸ ÁýÁߵǰí ÀÖ½À´Ï´Ù. ¿¹¹æÀº Æ÷±âÇÏ°í ÀÖ½À´Ï´Ù. ÇÏ·ç »¡¸® ¿ì¸®µµ Ç︮ÄÚ¹ÚÅÍ Á¦±ÕÄ¡·á¸¦ ³Î¸® ½ÃÇàÇÏ¿© À§¾ÏÀ» ¿¹¹æÇØ¾ß ÇÒ °ÍÀÔ´Ï´Ù. ÀÏÀü¿¡ ÇÑ ¸ðÀÓ¿¡¼­ ÀÌ Á¡À» °­Á¶ÇÏ¿© ¼³¸íµå¸° ¹Ù ÀÖ¾î ´ç½Ã µ¿¿µ»óÀ» ´Ù½Ã Çѹø ¼Ò°³ÇÕ´Ï´Ù. ÀϺ» ¸ðµ¨À» ÂüÁ¶ÇÏ¿© Àü±¹¹Î Á¦±ÕÄ¡·á¸¦ µµÀÔÇØ¾ß ÇÒ ½ÃÁ¡ÀÔ´Ï´Ù.

PPT PDF 2.8M

2017-4-4. ÀÌÁØÇà °­ÀÇ

2) Management of recurrent symptoms after per-oral endoscopic myotomy in achalasia

Forty-three of 441 patients (9.8%) had persistent or recurrent symptoms after POEM, of which 34 (8%) received 1 or more retreatments. Retreatment with laparoscopic Heller myotomy and retreatment with POEM showed a modest efficacy of 45% and 63%, respectively, whereas pneumatic dilatation showed a poor efficacy of only 0% to 20%, depending on the size of the balloon. Male patients were more likely to have retreatment failure than female patients (P = .038).

½ÇÆÐ »ç·Ê (persistent or recurrent symptoms)°¡ ´ë°­ 10%ÀÎ °ÍÀº ÀϹÝÀûÀÎ °Í °°½À´Ï´Ù. ¿©ÇÏÆ° POEM failure¿¡¼­ balloon dilatationÀº È¿°ú°¡ ³·°í POEMÀ» ´Ù½ÃÇϰųª Heller myotomy¸¦ ½ÃÇàÇØ¾ß ÇÒ °Í °°½À´Ï´Ù.

[ÀÌdz·Ä ±³¼ö´Ô comment] Ballon dilatation, ¼ö¼ú, POEM µî ¸ðµç Ä¡·á¿¡¼­ young male¿¡¼­ Ä¡·á ¼ºÀûÀÌ °¡Àå ³ª»Ú´Ù´Â °ÍÀº °øÅëÁ¡ÀÔ´Ï´Ù. High resolution manometry·Î ¾ÆÇü ºÐ¼®À» Ãß°¡Çصµ ¸¶Âù°¡ÁöÀÔ´Ï´Ù. ÀþÀº ³²ÀÚÀÇ host factor°¡ ÀÖÁö ¾Ê³ª »ý°¢µË´Ï´Ù. Neural networkÀÇ Àå¾Ö·ÎºÎÅÍ ½ÃÀÛÇÏ´Â Áúº´ÀÌÁö¸¸ ¿ì¸®´Â motor ÀÌ»ó¸¸ º¸°í ÀÖ½À´Ï´Ù. ¹®Á¦´Â ¿ì¸®°¡ Àß º¸Áö ¸øÇÏ°í ÀÖ´Â sensory Àå¾Öµµ ±ò·ÁÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. °ú°Å Heller myotomy ¼ö¼ú¿¡¼­´Â myotomy ÈÄ fundoplicationÀ» ÇÏ¿´´Âµ¥ ³Ê¹« tightÇÏ°Ô ½Ã¼úµÇ¸é dysphagia°¡ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ¶§´Â balloon dilatationÀÌ È¿°úÀûÀÔ´Ï´Ù. ±×·¯³ª POEM¿¡¼­´Â myotomy°¡ ºñ±³Àû Àß µÇ±â ¶§¹®¿¡ Áõ»óÀç¹ßÀÇ °æ¿ì balloon dilatationÀÇ È¿°ú°¡ ¶³¾îÁö´Â °ÍÀÔ´Ï´Ù.


2017-7-4.

[Àú³Î]

1) Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality

[ÀÌÁØÇà comment] (1) ±¹¹ÎÀÇ »ý°¢°ú data°¡ ¸Å¿ì ´Ù¸¨´Ï´Ù. ±¹¹ÎÀº °ËÁøÀ» ÅëÇÏ¿© ¾ÏÀÌ ¿¹¹æµÇ´Â °ÍÀ¸·Î ¾Æ´Âµ¥ Àü¹®°¡µéÀº ¾Ï »ç¸ÁÀÌ Á¶±Ý ÁÙ¾îµå´Â °Íµµ ÀǹÌÀÖ´Â ¼º°ú·Î »ý°¢ÇÕ´Ï´Ù. (2) À§ÃÔ¿µÀÌ ¾ÆÁ÷µµ °ËÁø¿¡ »ç¿ëµÇ´Â °ÍÀº nonsenseÀÔ´Ï´Ù. (3) À§³»½Ã°æ quality controlÀÌ °ÅÀÇ ¾ø´ø ½ÃÀýÀÇ ÀÚ·áÀ̹ǷΠÃÖ±Ù¿¡´Â ³»½Ã°æÀÇ È¿°ú°¡ ´õ ÁÁÀ» °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù.

[ÀÌdz·Ä ±³¼ö´Ô comment] ´ë±Ô¸ð »ç¾÷ÀÇ ÀÚ·áÀÌÁö¸¸ ¾Æ½¬¿î Á¡ÀÌ ÀÖ½À´Ï´Ù. º¸´Ù ÁÁÀº ÀڷḦ prospectiveÇÏ°Ô ¸ð¾Ò´õ¶ó¸é ´õ ÁÁ¾ÒÀ» °Í °°½À´Ï´Ù.

2) Longer Observation Time Increases Proportion of Neoplasms Detected by Esophagogastroduodenoscopy

[ÀÌÁØÇà ÇѸ¶µð] °ÇÁø À§³»½Ã°æ¿¡¼­ °Ë»ç½Ã°£ÀÌ ±æ¼ö·Ï, Á¶Á÷°Ë»ç¸¦ ¸¹ÀÌ ÇÒ¼ö·Ï Á¾¾çÀ» ¸¹ÀÌ ¹ß°ßÇÑ´Ù´Â µ¥ÀÌŸÀ̸ç, multivariate analysis¿¡¼­ °Ë»ç ½Ã°£ÀÌ Áß¿äÇÑ quality indicator¿´½À´Ï´Ù. Slow endoscopist¿Í fast endoscopistÀÇ Â÷ÀÌ´Â ÁÖ·Î dysplasiaÀÇ Â÷ÀÌ¿´°í ÁøÇ༺ À§¾ÏÀÇ Â÷ÀÌ´Â ¾ø¾ú½À´Ï´Ù. ¸Å¿ì Áß¿äÇÑ ÀÚ·á°¡ ¾Æ´Ò ¼ö ¾ø½À´Ï´Ù. ´Ù¸¸ ¿ì·Á½º·¯¿î °ÍÀº ³Ê¹« ¸¹Àº Á¶Á÷°Ë»çÀÔ´Ï´Ù. ³»½Ã°æ °Ë»ç ½Ã°£Àº 1:53-3:47¿´À¸¸ç, Á¶Á÷°Ë»ç°¡ 6.9-27.8%ÀÇ È¯ÀÚ¿¡¼­ ½ÃÇàµÇ¾ú°í, Á¾¾çÀº 0.14-0.32%¿¡¼­ ¹ß°ßµÇ¾ú½À´Ï´Ù. ´ë°­ 100°³ Á¶Á÷°Ë»ç¿¡¼­ 1°³ Á¾¾çÀÌ ³ª¿Ô´Ù´Â À̾߱âÀÔ´Ï´Ù. ÀúÀÇ ÀÓ»ó °æÇèÀ¸·Î ÆÇ´ÜÇϸé Á¶Á÷°Ë»ç Áß 1%¿¡¼­ Á¾¾çÀÌ ³ª¿Ô´Ù´Â °ÍÀº ³Ê¹« ³·Àº ¼öÄ¡ÀÎ °Í °°½À´Ï´Ù. °ÇÁø À§³»½Ã°æ¿¡¼­ Á¶Á÷°Ë»çÀÇ threshold°¡ ³Ê¹« ³·Àº °ÍÀº ¾Æ´ÑÁö ¿ì·ÁµË´Ï´Ù. ÀÌ ºÎºÐ¿¡ ´ëÇÏ¿© Á» ´õ »ìÆ캼 ÇÊ¿ä°¡ ÀÖÀ» °Í °°½À´Ï´Ù.


2017-6-27.

3Â÷ box simulator training course (ÀÚ¿øÀÚ) : 7¿ù 25ÀÏ (È­) - 7¿ù 26ÀÏ (¼ö)

ÀÌÇõ ±³¼ö´Ô: ´ÙÀ½ ESD animal model ½Ç½À ÀÏÁ¤À» Á¤ÇØÁֽñ⠹ٶø´Ï´Ù. MALToma Ç¥ÁØ protocol ¸¸µì½Ã´Ù.

±èÅÂÁØ ±³¼ö´Ô: ´ëÀå³»½Ã°æ box simulator ÈÆ·ÃÀ» À§ÇÑ °èȹÀ» Àâ¾ÆÁÖ¼¼¿ä.

[Àú³Î]

Diagnostic features of malignancy-associated pseudoachalasia APT 2017


2017-6-20.

[Àú³Î]

No Benefit From Platelet Transfusion for Gastrointestinal Bleeding in Patients Taking Antiplatelet Agents


2017-6-13.

[Pacemaker ȯÀÚÀÇ ³»½Ã°æ]

Pacemaker depedent patient: reprogramming (sensingÀ» ²ô´Â °Í)

Pacemaker independent patient: ±×³É ÇÒ ¼ö ÀÖ´Ù. bipolar ¼±È£. ³·Àº Àü·ù. Cut mode. Intermittent (ª°Ô ²÷¾î¼­ ´©¸¥´Ù). Grounding pad¸¦ ¸Ö¸® ºÙÀδ٠(´Ù¸®³ª Ç㸮). Àü·ù¸¦ ª°Ô ²÷¾î¼­ ´©¸¥´Ù.

ICD ±â´ÉÀÌ ÀÖ´ÂÁö ¾ø´ÂÁö ¾î¶»°Ô ¾Æ³ª¿ä? ECG response°¡ ¿À´ÂÁö ¾î¶»°Ô ¾ËÁö¿ä?

Pacemaker°¡ ¸Á°¡Áö°Å³ª shock wave°¡ trigger µÇ´Â °æ¿ì°¡ ÀÖ½À´Ï±î?

MagnetÀº ¹«½¼ ¿ªÇÒÀ» ÇÏ´Â °ÍÀΰ¡¿ä?

¸ðµç ȯÀÚ¸¦ consulting ÇÒ ¼ö ¾ø´Âµ¥¿ä.

°©ÀÚ±â ¾Ë°Ô µÇ¸é 3732¿¡ ÀüÈ­ÇÏ¿© »ó´ãÇսôÙ.


2017-5-30.

[Àú³Î]

1. Comprehensive Analysis of Adverse Events Associated With Per Oral Endoscopic Myotomy in 1826 Patients: An International Multicenter Study - A total of 1,826 patients underwent POEM. Overall, 156 AEs occurred in 137 patients (7.5%). A total of 51 (2.8%) inadvertent mucosotomies occurred. Mild, moderate, and severe AEs had a frequency of 116 (6.4%), 31 (1.7%), and 9 (0.5%), respectively. Multivariate analysis demonstrated that sigmoid-type esophagus (odds ratio (OR) 2.28, P=0.05), endoscopist experience <20 cases (OR 1.98, P=0.04), use of a triangular tip knife (OR 3.22, P=0.05), and use of an electrosurgical current different than spray coagulation (OR 3.09, P=0.02) were significantly associated with the occurrence of AEs.

2. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial


2017-5-23.

À̹ø ÁÖ ¼ö¿äÀÏ. ±èÅÂÁØ ±³¼ö´Ô MGR

À̹ø ÁÖ ±Ý¿äÀÏ one point lesson - ESD


1. Áõ·Ê ¸®ºä

5³â°£ ¾ðÄ£ Áõ¼¼°¡ ÀÖ¾ú°í Á¡Â÷ üÁßÀÌ ºüÁ³´ø ºÐÀÔ´Ï´Ù. °ú°Å ³»½Ã°æ ÈÄ ¿ª·ù¼º ½Äµµ¿°À¸·Î µéÀº ¹Ù ÀÖ´Ù°í ÇÕ´Ï´Ù. ±×·¯³ª, ³»½Ã°æ »çÁøÀ» ÀÚ¼¼È÷ º¸¸é EG junctionÀÌ tight ÇÏ°í ÇϺνĵµ°¡ ´Ã¾î³­ ¸ð¾çÀÔ´Ï´Ù. ½Äµµ Áõ»óÀÌ ÀÖ´Â »ç¶÷¿¡¼­ ÀÌ Á¤µµ ¼Ò°ßÀÌ º¸À̸é achalasia¸¦ ÀǽÉÇÒ ¼ö ÀÖ¾î¾ß ÇÕ´Ï´Ù.

Timed barium esophagography¿¡¼­ ÀüÇüÀûÀÎ ¼Ò°ßÀÌ ÀÖ¾ú½À´Ï´Ù. HRM¿¡¼­ LES relaxationÀÌ ÀüÇô º¸ÀÌÁö ¾Ê°í panesophageal pressurizationÀ» º¸ÀÌ°í À־ ÀüÇüÀûÀÎ type II achalasiaÀÔ´Ï´Ù. POEMÀ¸·Î Ä¡·áÇÏ¿´½À´Ï´Ù. Inner circular muscleÀ» µé¾î¿Ã¸®´Â ´À³¦À» °¡Áö¸é¼­ pushÇÏ¿© ÀýÁ¦ÇÏ°í ÀÖ½À´Ï´Ù. LES¿¡¼­´Â full thickness resectionÀ» ÇØ ÁÖ´Â °ÍÀÌ È¿°úÀûÀÔ´Ï´Ù. µû¶ó¼­ pneumoperitoneumÀÌ ¾à°£ »ý±â´Â °ÍÀº Å« ¹®Á¦°¡ ¾ø½À´Ï´Ù. (¹Î¾ç¿ø ±³¼ö´Ô)

2. High resoluation manometry Æǵ¶¹ý ¸®ºä

PDF 2.9M

PPT PDF 2.6M ³»ºÎ¿ë (¾ÏÈ£ ÀÖÀ½)

Conventional¿¡¼­´Â (1) resting LES pressure¿Í (2) swallowing ½Ã relaxationÀ» ¸ðµÎ µûÁ³´Âµ¥ HRM¿¡¼­´Â IRP, Áï (2) swallowing¿¡¼­ relaxationÀÌ µÇ´ÂÁö¸¸ º¸´Â °ÍÀÔ´Ï´Ù.

3. POEM¿¡ ´ëÇÑ ¹Î¾ç¿ø ±³¼ö´Ô comment

HRM Æǵ¶¹ýÀº achalasia Áø´Ü¿¡ ÃÖÀûÈ­ µÇ¾î ÀÖ½À´Ï´Ù.


[¹Îº´ÈÆ ±³¼ö´Ô Áú¹®]

SubtypeÀ» ³ª´©´Â °ÍÀº Àǹ̴Â?

[¹Î¾ç¿ø ±³¼ö´Ô ´äº¯]

°ú°Å¿¡´Â Ä¡·á ¹æ¹ýÀÌ ´Ù¾çÇÒ ¶§¿¡´Â subtypeÀÌ Àǹ̰¡ ÀÖ¾úÀ¸³ª Áö±ÝÀº ¸ðµÎ POEMÀ¸·Î Ä¡·áÇϹǷΠġ·á¹æħ °áÁ¤¿¡¼­´Â º° µµ¿òÀÌ µÇÁö ¾Ê°í ÀÖ½À´Ï´Ù. POEM °á°ú´Â type II¿¡¼­ ¸Å¿ì ÁÁ½À´Ï´ÙType I°ú type III´Â À̺¸´Ù ¸øÇÑ °Í °°½À´Ï´Ù. ƯÈ÷ type III´Â LES relaxation¿¡µµ ¹®Á¦°¡ ÀÖ°í body¿¡¼­´Â spastic motility abnormalityµµ ÀÖ´Â ÇüÅ·ΠÆǴܵǴµ¥, µÎ °¡Áö physiology ÀÌ»óÀ» POEM ÇÑ ¹æ¹ýÀ¸·Î Ä¡·áÇÏ´Â °ÍÀÎÁö¶ó È¿°ú°¡ ´Ù¼Ò ¶³¾îÁö´Â °Í °°½À´Ï´Ù.

* Âü°í: EndoTODAY Achalasia & POEM


2017-5-16

[Àú³Î]

1) Randomised clinical trial: addition of alginate-antacid (Gaviscon Double Action) to proton pump inhibitor therapy in patients with breakthrough symptoms

2) Acid-suppressing therapies and subsite-specific risk of stomach cancer


2017-5-2.

¸¶¾à·ù Àü»ê °³¹ßÀÌ ÁøÇà ÁßÀÔ´Ï´Ù. ÇâÈÄ ¸ðµç ¸¶¾àÀº Àǻ簡 Á÷Á¢ ÀÔ·ÂÇØ Áֽñ⠹ٶø´Ï´Ù.

¼ö¼úÀå portable ³»½Ã°æ¿¡ ´ëÇÑ Á¤Ã¥°ú Áõ·Ê ºÐ¼®Àº ¹Î¾ç¿ø ±³¼ö´Ô²² ºÎŹµå¸³´Ï´Ù.

5¿ù 18ÀÏ ¸ñ¿äÀÏ 18:30. One point lesson - hiatal hernia

2017-5-19 one point lesson (°­ÀÇ·Ï)

³»½Ã°æÀû NG tube insertion¿¡ ´ëÇÏ¿© (±èÅÂÁØ)


[Áõ·Ê 1]

´ëÀå¾Ï °¡Á··ÂÀÌ ¸¹Àº (¾Æ¹öÁö, ¾î¸Ó´Ï, µ¿»ý µî) ȯÀÚÀÇ A colon ´ëÀå¾ÏÀ̾ú½À´Ï´Ù (¿©¼º, ´ëÀå¾Ï Áø´Ü ´ç½Ã 40´ë ÃʹÝ). Áúº´ÀÇ À̸§¿¡ non-polyposis°¡ ºÙ¾îÀÖÁö¸¸ ±×·¡µµ ¸î °³ÀÇ ¿ëÁ¾ÀÌ ÀÖ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀÌ È¯ÀÚ¿¡¼­µµ ´ëÀå¾Ï ÀÌ¿Ü¿¡ 6°³ÀÇ ¿ëÁ¾ÀÌ ÀÖ¾ú½À´Ï´Ù.


Ascending colon, cecum, appendix, and terminal ileum, right, hemicolectomy:
Adenocarcinoma, moderately differentiated, cecum:
1) tumor size: 5x3.5 cm
2) extension to the pericolic adipose tissue
3) endolymphatic tumor emboli: present
4) focal mucin production and micropapillary pattern
5) negative resection margins (proximal, 10 cm; distal, 13.7 cm)
6) metastasis to 1 out of 33 regional lymph nodes, (1/33: "right colic A", 0/1; "mid colic", 0/3; pericolic, 1/29)
. Multiple tubular adenomas, high-grade dysplasia (x6)
. Appendix with no diagnostic abnormalities recognized
AJCC Pathologic Stage IIIB (T3, N1, MX)

À¯ÀüÀÚ °Ë»ç¿¡¼­ MSI-H (BAT 25: unstable, BAT 26: unstable, D5S346: unstable, D17S250: stable, D2S123: unstable)°¡ ³ª¿Ô°í MLH1 À¯ÀüÀÚÀÇ frameshift mutationÀÌ È®ÀεǾú½À´Ï´Ù.

´ëÀå¾Ï ¼ö¼ú 10³â ÈÄ À§¾Ïµµ ¹ß°ßµÇ¾î ESD¸¦ ÇÏ¿´½À´Ï´Ù.


Stomach, endoscopic submucosal dissection:
Early gastric carcinoma
1. Location :angle
2. Gross type : EGC type IIc
3. Histologic type : tubular adenocarcinoma, well differentiated
4. Histologic type by Lauren : intestinal
5. Size of carcinoma : (1) longest diameter, 16mm (2) vertical diameter,11 mm
6. Depth of invasion : invades mucosa (lamina propria) (pT1a)
7. Resection margin : free from carcinoma(N), safety margin : distal 11 mm, proximal 10 mm, anterior 16 mm, posterior 22 mm
8. Lymphatic invasion : not identified(N)
9. Venous invasion : not identified(N)
10. Perineural invasion : not identified(N)
11. Microscopic ulcer : absent
12. Histologic heterogeneity: absent

À§¾Ï ¼ö¼ú 2³â ÈÄ ½ÊÀÌÁöÀåÀÇ SMT-like cancer°¡ ¹ß°ßµÇ¾î ¼ö¼úÀ» ÇÏ¿´½À´Ï´Ù.


Duodenal Carcinoma
(1) Histologic type: Signet ring cell carcinoma with mucin production (60%)
(2) Histologic Grade: G3 (poorly differentiated)
(3) Precursor lesion: not applicable
(4) Invasive tumor size: greatest dimension (3cm)
(5) T4: Tumor directly invades pancreas and periduodenal soft tissue
(6) N1: Metastasis 2 out of 7 regional lymph nodes, (2/7: LN8, 0/1; LN12, 0/4; periduodenal, 2/2)
(7) cM0: Clinically No distant metastasis
(8) Involvement of portal vein: absent
(9) Margin status: Duodenal margin: negative (safety margin: 3 cm); Pancreas neck margin: negative
(10) Perineural and neural invasion: present
(11) Lymphovascular invasion: present
(12) Autolysis, gallbladder

[Çؼ³] HNPCC-associated cancer¿¡´Â ´ëÀå¾Ï ÀÌ¿Ü¿¡ Àڱ󻸷¾Ï (lifetime risk 54%), ³­¼Ò¾Ï (lifetime risk 10-12%), À§¾Ï (lifetime risk 13% or higher in Korea), °£´ãµµ¾Ï, ¼ÒÀå¾Ï, ½ÅÀå¾Ï µîÀÌ ÀÖ½À´Ï´Ù.


[Àú³Î ¸®ºä]

Noncurative resection ȯÀÚÀÇ eCure scoring system (Hatta. Am J Gastroenterol 2017)

* Âü°í: EndoTODAY Non-curative resection


2017-4-25.

ÀÔ¿øȯÀÚ ³»½Ã°æ ãÁ Ç×»ó º¸È£ÀÚ°¡ °è¼Å¾ß Çϴ°¡¿¡ ´ëÇÏ¿© - ÁøÁ¤ ¿©ºÎ¿Í ¹«°üÇÏ°Ô Áø´Ü ³»½Ã°æÀº º¸È£ÀÚ ¾øÀÌ, Ä¡·á³»½Ã°æ°ú ERCP´Â º¸È£ÀÚ °è½Å »óÅ¿¡¼­ ½Ã¼ú. ±ÞÇÏ¸é ¿¬¶ôó¸¸ È®ÀÎÇÑ ÈÄ ½ÃÇàÇÒ ¼ö ÀÖ´Ù.

³»½Ã°æ »çÁø ÃÔ¿µ ½Ã Àß ÂïÈ÷°í ÀÖ´ÂÁö ³»½Ã°æ system È­¸éµµ Á¾Á¾ È®ÀÎÇØ ÁÖ¼¼¿ä.


[Àú³Î]

1) Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma Ann Oncol 2017

2) Diagnosis of gastro-oesophageal reflux disease is enhanced by adding oesophageal histology and excluding epigastric pain APT 2017

GERD¿¡¼­ Ư¡ÀûÀÎ histology°¡ ÀÖ½À´Ï´Ù (basal cell hyperplasia, papilla elongation). pH-impedence¸¦ ÇÏÁö ¾Ê¾Ò´Ù´Â °ÍÀÌ Áß¿äÇÑ ´ÜÁ¡ÀÔ´Ï´Ù.

Rome-III(?)¿¡¼­´Â reflux-like FD¸¦ FD¿¡¼­ ¹èÁ¦ÇÏ°í GERD·Î ºÒ·¶´Âµ¥, ÃÖ±Ù ÀÚ·á¿¡ ÀÇÇϸé reflux-like FD°¡ ³ª¸§ Àǹ̰¡ ÀÖ´Ù°í »ý°¢µË´Ï´Ù.

Epigastric painÀ» ¹èÁ¦ÇÏ´Â °ÍÀÌ GERD¿¡ µµ¿òµÈ´Ù´Â ³»¿ëÀÌ ÀÖ¾ú½À´Ï´Ù. ¿ì¸®³ª¶ó¿¡¼­´Â heartburnÀ̶ó´Â ¿ë¾î°¡ ¾ø±â ¶§¹®ÀÎÁö ¾Ë ¼ö ¾øÁö¸¸, GERD ȯÀÚ°¡ º¹Åë, ¼Ó¾²¸², »ý¸ñ µî ´Ù¾çÇÑ Áõ»óÀ¸·Î ³»¿øÇÕ´Ï´Ù (¾Æ·¡ ±è³ª¿µ ±³¼ö´Ô °­ÀÇ ÀÚ·á ÂüÁ¶). »ç½Ç ¹Ì±¹¿¡¼­µµ 'heartburn'À» ¿ÜÄ¡¸é¼­ ³»¿øÇϴ ȯÀÚ°¡ ¾ÆÁÖ ¸¹Àº °ÍÀº ¾Æ´Ï¶ó°í ÇÕ´Ï´Ù. ¿ì¸®ÀÇ ¾î·Á¿òÀº ¿µ¾î Ç¥ÇöÀ¸·Î epigastric painÀ¸·Î ¾µ ¼ö ¹Û¿¡ ¾ø´Â ȯÀÚ Áß GERD°¡ ÀûÁö ¾Ê´Ù´Â Á¡ÀÔ´Ï´Ù. Epigastric pain ȯÀÚ¸¦ ¹èÁ¦Çϸé GERD¸¦ ³õÄ¥ ¼ö ÀÖ½À´Ï´Ù.

9ȸ ºÐ´ç¼­¿ï´ëº´¿ø ¿¬¼ö°­Á ±è³ª¿µ ±³¼ö´Ô °­ÀÇ·Ï Áß

ÀÌ¿¡ ´ëÇÏ¿© ÀÌdz·Ä ±³¼ö´Ô²²¼­ Áß¿äÇÑ comment¸¦ ÇØ Áּ̽À´Ï´Ù. Áõ»óÀÇ À§Ä¡¸¦ point out Çϵµ·Ï Áö½ÃÇÏ¸é µµ¿òÀÌ µÈ´Ù°í ÇÕ´Ï´Ù. '¼ÓÀÌ ¾ÆÇÁ´Ù'°í ¿À½Å ȯÀÚ Áß ¾îµð°¡ ¾ÆÇÂÁö ¤¾îº¸µµ·Ï Çϸé retrosternal area¸¦ ÁöÀûÇÏ´Â »ç¶÷µµ ÀÖ°í ¸íÄ¡³ª ¹è²Å ÁÖÀ§¸¦ ÁöÀûÇÏ´Â »ç¶÷µµ Àֱ⠶§¹®ÀÔ´Ï´Ù. GERD ȯÀÚ´Â ´ëºÎºÐ º¹ºÎ°¡ ¾Æ´Ï¶ó ÈäºÎ¸¦ ÁöÀûÇÕ´Ï´Ù.

GERD ȤÀº FD ÀÇ½É È¯ÀÚ°¡ ¿À¸é "¾îµð°¡ ºÒÆíÇÑÁö ¼Õ°¡¶ôÀ¸·Î ¤¾îº¸¼¼¿ä"¶ó°í ¸»Çغ¾½Ã´Ù. ¹°·Ð overlap Áõ»óÀ» °¡Áø »ç¶÷µµ ÀÖ½À´Ï´Ù¸¸... ´ëºÎºÐÀÇ °æ¿ì¿¡´Â Å©°Ô µµ¿òÀÌ µÉ °Í °°½À´Ï´Ù.


2017-4-18.

4¿ù 20ÀÏ ESD animal model ¿¬½À¿¡ ´ÊÁö ¾Êµµ·Ï ¼­·Î µµ¿Í¼­ ¼­µÑ·¯ Áֽñ⠹ٶø´Ï´Ù.

¿À´Ã ³»½Ã°æÇÐȸ Áý´ãȸ°¡ ÇѾç´ë¿¡¼­ ¿­¸³´Ï´Ù. ¿ÀÈÄ 4½Ã 30ºÐ 1Â÷ Ãâ¹ß (¾Ï¼¾ÅÍ 1Ãþ ·Îºñ) ¿¹Á¤ÀÔ´Ï´Ù.


[Àú³Î]

1) Serum gastrin and cholecystokinin are associated with subsequent development of gastric cancer in a prospective cohort of Finnish smokers

2) Randomised clinical trial: rifaximin versus placebo for the treatment of functional dyspepsia

Gut dysbiosys¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô½À´Ï´Ù. Rifaximin 400 mg three times a day for 2 weeks.


[ÃÖ±Ù ³»½Ã°æ comment]

°­ÀÇ, book reading, box simulator ¿¬½À, hands-on, ¸ñ¿ä³»½Ã°æÁý´ãȸ Âü¼® µî ¸î °³¿ùÀÇ Áغñ ³¡¿¡ µåµð¾î 4³âÂ÷ Àü°øÀÇ ¼±»ý´ÔµéÀÌ µ¶¸³ÀûÀ¸·Î ³»½Ã°æÀ» Çϱ⠽ÃÀÛÇÏ¿´½À´Ï´Ù. ±×·±µ¥ µ¶¸³ÇÑ Ã¹ ³¯ µÎ ºÐ ¼±»ý´Ô²²¼­ ¾ÏÀ» ¹ß°ßÇϼ̽À´Ï´Ù. Á¤¸» ´ë´ÜÇÑ ÀÏÀ̶ó°í »ý°¢ÇÕ´Ï´Ù. °¨»çÇÏ°í ÃàÇÏÇÕ´Ï´Ù.

ÀüÁ¤ºÎ À§¾Ï¿¡ ´ëÇÑ ESD ÈÄ ÃßÀû°üÂû ÇÏ´ø ȯÀÚ¿¡¼­ ¹ß°ßµÈ À§ fundus cancerÀÔ´Ï´Ù. ³»½Ã°æÀ» óÀ½ ½ÃÀÛÇϽô ºÐµéÀÌ miss Çϱ⠽¬¿î À§Ä¡ÀÇ ¾ÏÀε¥ ¾ÆÁÖ Àß ¹ß°ßÇϼ̽À´Ï´Ù.

Pyriform sinus cancer·Î Ä¡·á¹ÞÀº ȯÀÚÀÔ´Ï´Ù. ÃÖ±Ù dysphagia°¡ ¹ß»ýÇÏ¿© ½ÃÇàÇÑ ³»½Ã°æÀε¥ ½Äµµ¾ÏÀÌ ÀÖ¾ú½À´Ï´Ù. Á¤¸» Àß Çϼ̴µ¥... ´õ ÀßÇ϶ó´Â Àǹ̷Πcomment¸¦ ºÙÀÔ´Ï´Ù. NBI¸¦ Àû¿ëÇϰųª Lugol solutionÀ» »Ñ·Á¼­ ÀÚ¼¼È÷ °Ë»çÇÏ¿´´õ¶ó¸é ´õ ÁÁ¾ÒÀ» °Í °°½À´Ï´Ù. ¿©ÇÏÆ° very good.

4³âÂ÷ Àü°øÀÇ ¼±»ý´Ô ÇÑ ºÐ²²¼­ ÃÖ±Ù ÀÚ½ÅÀÌ °Ë»çÇÑ À§¾Ï ȯÀÚ ID¸¦ ¾Ë·ÁÁּż­ °ËÅäÇÏ°í comment¸¦ ºÙ¿©º¸¾Ò½À´Ï´Ù. Âü°íÇϽñ⠹ٶø´Ï´Ù.


2017-4-11.

4³âÂ÷ Àü°øÀÇ ³»½Ã°æ supervision Àß ÇØ Áֽñ⠹ٶø´Ï´Ù. Á¶±ÝÀÌ¶óµµ ÀÌ»óÇÏ¸é »çÁø Âï°í Á¶Á÷°Ë»ç¸¦ ÇÑ ÈÄ ¹®ÀÇÇÑ´Ù.

4¿ù 11ÀÏ Àú³á 6½Ã ¾Ï¼¾ÅÍ ³»½Ã°æ½Ç ȸÀǽÇ. One point lesson (ESD video review) --> 4¿ù 20ÀÏ ESD ¿¬½À (³»½Ã°æ ÀÏÁ¤ °ü·ÃÇÏ¿© ºÎŹÇØ µÎ½Ã±â ¹Ù¶ø´Ï´Ù). ³¡³ª°í ¸ÆÁÖ ÇÑ ÀÜ.

4¿ù 18ÀÏ (È­) ÇѾç´ëÇб³ ³»½Ã°æ Áý´ãȸ - 4¹ø°: EVACÀ¸·Î Ä¡·áµÈ esophagectomy with 3-field LN dissection ÈÄ ¹ß»ýÇÑ anastomotic leakage. ±èÅÂ¿Ï ¼º±Õ°ü´ëÇб³ »ï¼º¼­¿ïº´¿ø

4¿ù ¸¶Áö¸· ÁÖ research ¹ßǥȸ


[Áõ·Ê]

EGD·Î Àß º¸ÀÌÁö ¾Ê¾Æ duodenoscopy·Î È®ÀÎÇÏ¿´´ø AoV cancer


[Àú³Î]

1) Determinants of reflux-induced chronic cough

CONCLUSIONS: The presence of a larger volume of refluxate and oesophageal exposure to reflux for a longer period of time seems to play an important role in inducing cough, while the acidity of the refluxate seems to be less relevant. This helps explain the observation that most patients with chronic cough tend not to benefit from acid inhibitory treatment.

2) Dual-focus versus conventional magnification endoscopy for the diagnosis of superficial squamous neoplasms in the pharynx and esophagus: a randomized trial


2017-4-4.

[Mini-lecture] ÀÌÁØÇà Ư°­ - PACS¿¡¼­ ³»½Ã°æ »çÁøÀ» ¹Þ¾Æ Poweropint¿¡ ¿¹»Ú°Ô ³Ö´Â ¹æ¹ý (ÀÛÀº file Å©±â À¯ÁöÇϸ鼭)

1) PACS È­¸éÀ¸·Î µé¾î°£´Ù.

2) ¸¶¿ì½º ¿ìÃø buttonÀ» ´­·¯¼­ AnnotationÀ» NoneÀ¸·Î ¼±Á¤ÇÑ´Ù. À̶§ ¿ìÃø »ó´ÜÀÇ Á¤º¸´Â »ç¶óÁöÁö¸¸ ÁÂÃø »ó´ÜÀÇ Á¤º¸´Â »ç¶óÁöÁö ¾Ê´Â´Ù (Screencapture¹æ½ÄÀ¸·Î ¸¸µé¾îÁø fileÀ̱⠶§¹®).

3) ¸¶¿ì½º ¿ìÃø buttonÀ» ´­·¯¼­ Export¸¦ ÇÑ´Ù. Àû´çÇÑ file À̸§À» ºÙÀδÙ. File À̸§¿¡´Â °³ÀÎÁ¤º¸°¡ µé¾î°¡Áö ¾Ê¾Æ¾ß ÇÑ´Ù.

4) Powerpoint¿¡¼­ ¿øÇÏ´Â »çÁøÀ» »ðÀÔÇÑ´Ù. À̶§ ¼±ÅÃÇÑ »çÁøµéÀÌ °ãÃļ­ º¸ÀδÙ.

5) Powerpoint »ó´ÜÀÇ ºü¸¥½ÃÇà µµ±¸¸ðÀ½ÀÇ ¿ìÃø »ó´Ü¿¡ ÀÖ´Â ÀÚ¸£±â ±â´ÉÀ» ÀÌ¿ëÇÏ¿© »çÁøÀ» ÀÏÁ¤ÇÑ Å©±â·Î ÀÚ¸¥´Ù. ù »çÁøÀ» ÀÚ¸£°í ³­ ÈÄ µÎ¹ø° »çÁøÀ» ÀÚ¸£¸é Àû´çÈ÷ µé·¯ºÙÀ¸¸é¼­ Á¤È®È÷ °°Àº Å©±â°¡ µÈ´Ù.

6) µµ±¸¸ðÀ½ ¿ì»ó´ÜÀÇ Å©±â ±â´ÉÀ» ÀÌ¿ëÇÏ¿© »çÁøÀÇ Å©±â¸¦ ³ôÀÌ 10cm·Î º¯°æÇÑ´Ù.

7) »çÁøÀ» dragÇÏ¿© Àû´çÇÑ °÷¿¡ À§Ä¡½ÃŲ´Ù. °£È¤ ³ôÀÌ°¡ ¸ÂÁö ¾ÊÀ¸¸é µµ±¸¸ðÀ½ÀÇ Á¤·Ä - ¸ÂÃã - À§ÂÊ ¸ÂÃã ±â´ÉÀ» ÀÌ¿ëÇÏ¿© Á¤È®È÷ ³ôÀ̸¦ ¸ÂÃá´Ù.


2017-3-28.

4¿ù 20ÀÏ ESD animal model Áغñ »óȲ Á¡°Ë (ÀÌÇõ) - 3¿ù 28ÀÏ, 4¿ù 11ÀÏ Àú³á 6½Ã ³»½Ã°æ½Ç ȸÀǽÇ: ³»½Ã°æ video ¹× Áõ·Ê °ËÅä

Indigocarmine °ü·Ã ³»¿ë Á¤¸®ÇÏ¿© °Ô½ÃÇÒ ¼ö ÀÖ´Â formÀ¸·Î Á¤¸® (±èÅÂÁØ)

1. NS mix ÀÎ °æ¿ì (ENI) : 1 cc mix
2. Glycerin mix ÀÎ °æ¿ì (EGI)
- 0.1 cc ÀÌÇÏ (±èÀçÁØ ±³¼ö´Ô ESD)
- 0.5 cc (ESD ±âº», ±è¿µÈ£ ±³¼ö´Ô)
- 2cc (È«¼º³ë ±³¼ö´Ô colon ESD)

´ëÀå³»½Ã°æ, ´ëÀå EMR °ü·Ã antiplatelet, anticoagulation Á¡°Ë (±èÅÂÁØ) - ÀÏ¹Ý ´ëÀå³»½Ã°æ¿¡¼­µµ °°Àº policy¸¦ »ç¿ëÇϱâ·Î ÇÔ

Hp ÇÐȸ ¹ßÇ¥ÀÚ ¸®Çã¼³ - ´ÙÀ½ ÁÖ È­¿äÀÏ ¿ÀÀü

Box simulator »õ·Î ±¸ÀÔ. ÁøÇà»óȲ º¸°í (¹Î¾ç¿ø) - ÀÏ´Ü ±¸ÀÔÇϱâ·Î ÇÔ


[Áõ·Ê]

ÀüÀÌÇßÀ» °Í °°Áö ¾ÊÀº À§¾Ï¿¡¼­ ¸²ÇÁÀýÀÌ Ä¿Á³À¸¸é (1) lymphoma (2) TB, (3) Castleman's disease µîÀ» °í·ÁÇØ¾ß ÇÕ´Ï´Ù.

* ±³¼ö´Ôµé comment: ¹ßÇ¥´Â formalÇÑ ÀÏÀÔ´Ï´Ù. ÀÚ·á ÁغñºÎÅÍ ¹ßÇ¥±îÁö formal ÇÏ°Ô ÁøÇàÇÏ¿© Áֽñ⠹ٶø´Ï´Ù. ¾àÀÚ »ç¿ë µîÀ» ÁÖÀÇÇսôÙ.


[Àú³Î]

The influence of procedural volume and proficiency gain on mortality from upper GI endoscopic mucosal resection Gut 2016


2017-3-21.

³»½Ã°æ ºÎºÐº° ÇöȲ Á¡°Ë (5) - ´ëÀå ³»½Ã°æ (±èÀº¶õ): Ç×ÀÀ°íÁ¦ Ç×Ç÷¼ÒÆÇÁ¦ µî

1) °íÀ§Çè ȯÀÚ¿Í aspirin ÀÌ¿ÜÀÇ ¾àÀ» µå½Ã´Â ºÐÀº consult¸¦ ÇÑ ÈÄ °Ë»ç

2) ÀúÀ§Çè ȯÀÚ°¡ aspirinÀ» ´Üµ¶À¸·Î µå½Ã´Â °æ¿ì´Â 4ÀÏ ²÷°í ½Ã¼úÇÑ´Ù. Ȥ½Ã ȯÀÚ°¡ ¾àÀ» ²÷Áö ¾Ê°í ÀåÁ¤°á ÈÄ ¿À½Å

3) Biopsy³ª polypectomy ÈÄ warfarinÀº ´çÀÏ Àú³á º¹¿ëÇÏ°í, ´Ù¸¥ ¾àÁ¦´Â ½Ã¼ú ´ÙÀ½ ³¯

µÅÁö stomach ÀÌ¿ëÇÑ ESD ÀÏÁ¤: 4¿ù 20ÀÏ ¸ñ¿äÀÏ 6pm - Àå¼Ò, ½Ã½ºÅÛ, ³»½Ã°æ, °¨¿° °ü¸®, °£È£»ç µî Á¦¹Ý »çÇ×À» È®ÀÎÇØ Áֽñ⠹ٶø´Ï´Ù (´ã´ç: ÀÌÇõ ±³¼ö´Ô). »çÀü ¸î ¹øÀÇ °øºÎ ¸ðÀÓÀ» ÁغñÇÏ¿´½À´Ï´Ù. 3¿ù 28ÀÏ Àú³á 6½Ã ³»½Ã°æ½Ç ȸÀÇ½Ç (ESD video review).

ESD³ª EMRÀ» À§ÇÑ submucosal fluid Á¤¸®. Indigocarmine, epinephrine µî ¼¯´Â ¹æ¹ýÀÌ ´Ù¾çÇÕ´Ï´Ù. Hyaluronic acid µîµµ ¾Ö¸ÅÇÏ°í... Bleeding control¿¡ »ç¿ëÇÏ´Â fluidµµ Á¤¸®µÇÁö ¾Ê¾Ò°í... ÇöȲÀ» ÆľÇÇÏ¿© ÃÑÁ¤¸® ÇսôÙ. (±èÅÂÁØ ±³¼ö´Ô)

4¿ù 8ÀÏ (Åä) Hp ÇÐȸ ¸¹ÀÌ Âü¼®ÇØ Áֽñ⠹ٶø´Ï´Ù.


[Áõ·Ê]

°æ°è°¡ ºÒºÐ¸íÇÑ ÇÔ¸ôÇü º´¼Ò·Î clipping ÈÄ subtotal gastrectomy ÇÏ¿´À¸³ª surgical resection margin positive·Î ³ª¿Í¼­ total gastrectomy·Î º¯°æÇÑ °æ¿ì


[Àú³Î]

1) Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency Gastroenterology 2017

California¿¡ º»ºÎ¸¦ µÐ ¹Ì±¹¿¡¼­ °¡Àå Å« managed care planÀÎ Kaiser PermanenteÀÇ ´ë±Ô¸ð ¿¬±¸ÀÔ´Ï´Ù.

2) Abdominal Compression by Waist Belt Aggravates Gastroesophageal Reflux, primarily by Impairing Esophageal Clearance Gastroenterology 2017

GERDÀÇ nonpharmacologic treatment¿¡ ´ëÇÑ Áõ°Å¸¦ ã¾Æ°¡´Â ÀÛ¾÷À̶ó°í º¸ÀÔ´Ï´Ù. Intraabdominal pressure°¡ GERD¿Í °ü·ÃÀÌ ÀÖ°í ƯÈ÷ º¹¾ÐÀÌ ³ô¾ÆÁö¸é acid clearance°¡ ´Ê¾îÁ®¼­ Barrett esophagusÀÇ À§ÇèÀÌ ÀÖ´Ù´Â ¼Ò°ßÀÔ´Ï´Ù.

Result: ... The pattern of impaired clearance was that of rapid re-reflux after peristaltic clearance.

Conclusion: In a prospective study of patients with esophagitis or Barrett's esophagus, we found belt compression increased acid reflux following a meal. The intragastric pressure rise inducing this effect is well within the range associated with differing waist circumference and likely to be relevant to the association between obesity and reflux disease.


2017-3-14.

³»½Ã°æ ºÎºÐº° ÇöȲ Á¡°Ë (4) - ³»½Ã°æ (¹Îº´ÈÆ)

µÅÁö stomach ÀÌ¿ëÇÑ ESD ÀÏÁ¤À» Àâ¾Ò½À´Ï±î? 4¿ù 20ÀÏ ¸ñ¿äÀÏ 6pm

³»½Ã°æÇÐȸ Áý´ãȸ ¹ßÇ¥ Áõ·Ê´Â Á¤Çß½À´Ï±î?

Ç×ÀÀ°íÁ¦ Ç×Ç÷¼ÒÆÇÁ¦ °øÁö ¹ÞÀ¸¼Ì½À´Ï±î? (±èÀº¶õ ±³¼ö´Ô. 2017-3-21)

´ëÀå ³»½Ã°æ °ü·Ã ¿©·¯ À̽´¸¦ Àü´ÞÇÏ¿´½À´Ï±î? (È«¼º³ë ±³¼ö´Ô. 2017-3-21)


[Áõ·Ê]

½ÊÀÌÁöÀå ±Ë¾ç ÇùÂøºÎ¿¡¼­ ±Ë¾çÀÌ Àç¹ßÇÏ¸é °üÂûÀÌ ¾î·Æ±â ¶§¹®¿¡ Áø´Üµµ ¾î·Æ½À´Ï´Ù.

°ú°Å ½ÊÀÌÁöÀå±Ë¾çÀ¸·Î ÀÎÇÑ ÇùÂøÀÌ ÀÖ´ø ȯÀÚÀÔ´Ï´Ù. ÇãÇ÷¼º ½ÉÁúȯÀ¸·Î coronary stent ÈÄ dual antiplatelet Ä¡·á¸¦ ¹Þ°í ÀÖ´ø Áß melena°¡ ¹ß»ýÇÏ¿´½À´Ï´Ù. ù ³»½Ã°æ¿¡¼­ ½ÊÀÌÁöÀå ÇùÂøºÎÀÇ ¹ßÀûÀº ÀÖ¾úÀ¸³ª ¶Ñ·ÇÇÑ ÃâÇ÷ ¼Ò°ßÀº ¾ø¾ú´ø °Í °°½À´Ï´Ù. ´ç½Ã¿¡´Â ½ÊÀÌÁöÀå Á¦2ºÎ±îÁö °üÂûÇÏÁö ¸øÇß½À´Ï´Ù.

PPI¸¦ »ç¿ëÇÏ¿´À¸³ª ÃâÇ÷ÀÌ °è¼ÓµÈ´Ù°í ÀǷڵǾî Áï½Ã ³»½Ã°æ Àç°ËÀ» ÇÏ¿´½À´Ï´Ù. ¾à°£ÀÇ ÀúÇ×°¨Àº ÀÖ¾úÀ¸³ª ÇùÂøºÎ¸¦ Åë°úÇØ º¸¾ÒÀ» ¶§, Á¼¾ÆÁø ¹Ù·Î ±×°÷¿¡¼­ oozingÀ» µ¿¹ÝÇÑ ±Ë¾çÀ» È®ÀÎÇÒ ¼ö ÀÖ¾ú½À´Ï´Ù. Injection ÈÄ monopolar coagulationÀ¸·Î ÁöÇ÷ÇÏ¿´½À´Ï´Ù. ÇâÈÄ symptomatic stricture ¹ß»ý °¡´É¼ºÀ» ¼³¸íÇÏ¿´°í, antiplatelet µå½Ã´Â ÇÑ Æò»ý PPI¸¦ ÇÔ²² µå½Ç °ÍÀ» ±ÇÇß½À´Ï´Ù.


[Àú³Î]

1. Doppler Endoscopic Probe Monitoring of Blood Flow Improves Risk Stratification and Outcomes of Patients with Severe Non-Variceal Upper Gastrointestinal Hemorrhage. - Doppler probe-guided endoscopic hemostasis significantly reduced 30 day rates of rebleeding, surgery, and major complications

PDF

¹Îº´ÈÆ ±³¼ö´Ô comment: È¿°úÀûÀÎ ³»½Ã°æ Ä¡·á ÈÄ ÀçÃâÇ÷·üÀÌ ³·±â ¶§¹®¿¡ Doppler±îÁö »ç¿ëÇÒ ÇÊ¿ä°¡ ÀÖÀ»Áö Àǹ®ÀÔ´Ï´Ù. ƯÈ÷ ¿ì¸®³ª¶ó¿¡¼­´Â adherent clotµµ Àû±ØÀûÀ¸·Î Á¦°ÅÇÏ¿© Ä¡·áÇÏ°í Àֱ⠶§¹®¿¡ ´õ¿í ±×·¯ÇÕ´Ï´Ù.

2. Menopausal hormone therapy and the risk of esophageal and gastric cancer - Sweden ¿¬±¸. Ever-users had decreased ORs of esophageal adenocarcinoma (OR=0.62, 95% CI 0.45-0.85, n=46), gastric adenocarcinoma (OR=0.61, 95% CI 0.50-0.74, n=123) and esophageal squamous cell carcinoma (OR=0.57, 95% CI 0.39-0.83, n=33).

ÀÌÇõ ±³¼ö´Ô comment: ½Äµµ ¼±¾Ï, ½Äµµ SCC, À§¾Ï Healthy user effect¿¡ ÀÇÇÑ bias¸¦ °í·ÁÇØ¾ß ÇÕ´Ï´Ù.

ÀÌÁØÇà comment: ´Ù¸¥ ¾Ï dataµµ ÀÖÀ» °ÍÀÌ°í ´Ù¸¥ ¾Ïµéµµ ÁÙ¾ú´ÂÁö¸¦ º¸¸é bias¸¦ Æò°¡Çϴµ¥ µµ¿òÀÌ µÉ °ÍÀε¥ ½Äµµ¾Ï°ú À§¾Ï¸¸ º¸¿©Á־ ¾Æ½±½À´Ï´Ù.


2017-3-7.

³»½Ã°æ ºÎºÐº° ÇöȲ Á¡°Ë (3): ÀÀ±Þ½Ç (±èÅÂÁØ).
- 2017/2 EGD 61, Colonoscopy 18, Sigmoidoscopy 6, ½ÄµµÀ̹°Á¦°Å¼ú 7, Volvulus 5
- ÀÀ±Þ ȯÀÚ, ÃâÇ÷ ȯÀÚ È¤Àº °£Áúȯ (EVL) ȯÀÚ sedation? Midazolam aloneÀ¸·Î õõÈ÷ »ç¿ëÇÑ´Ù. ÃâÇ÷ȯÀÚ³ª °£Áúȯ ȯÀÚ¶ó°í
- ½Ã¼ú ÀüÈÄ monitoring: ÀÎÅÏ ¼±»ý´Ô keepÀ» ¿øÄ¢À¸·Î ÇÑ´Ù.

µÅÁö stomach ÀÌ¿ëÇÑ ESD ÀÏÁ¤À» Àâ¾Ò½À´Ï±î?

³»½Ã°æÇÐȸ Áý´ãȸ ¹ßÇ¥ Áõ·Ê´Â Á¤Çß½À´Ï±î?

Ç×ÀÀ°íÁ¦ Ç×Ç÷¼ÒÆÇÁ¦ °øÁö ¹ÞÀ¸¼Ì½À´Ï±î? (±èÀº¶õ ±³¼ö´Ô)

´ëÀå ³»½Ã°æ °ü·Ã ¿©·¯ À̽´¸¦ Àü´ÞÇÏ¿´½À´Ï±î?


³»½Ã°æ½Ç hands-on training ¹× ½Ã¼úÀÚ ºÎÁ· º¸ÃæÀ» À§ÇÏ¿© ¿©·¯ ±³¼ö´Ôµé²²¼­ µµ¿ÍÁּż­ °¨»çÇÕ´Ï´Ù.

±ºÀÎ 5¸í ºÎÁ· »óȲ¿¡¼­ ³»½Ã°æ½Ç¿¡¼­ ¿­½ÉÈ÷ ÀÏÇØ Áּż­ °¨»çÇÕ´Ï´Ù.

³»½Ã°æ ÀÚ¼¼: °¡´ÉÇÏ¸é ¼­¼­ °Ë»çÇսôÙ.

³»½Ã°æ °Ë»ç ¹× ¿Ü·¡ ½ÃÀ۽ð£À» Àß Áöŵ½Ã´Ù.

3/14 È­ °£È£¼¼¹Ì³ª, 3/16 4pm box simulator for military physician, 3/17 ±Ý debriefing, 4/18 ³»½Ã°æÇÐȸ Áý´ãȸ (°í·Á´ë)

[Àú³Î 1] 2017³â 2¿ùÈ£ Gastroenterology¿¡ ÀӽŰú ³»½Ã°æ¿¡ ´ëÇÑ ¹Ì±¹ registry °á°ú°¡ ¹ßÇ¥µÇ¾ú½À´Ï´Ù. °á·ÐÀº ¾Æ·¡¿Í °°¾Ò½À´Ï´Ù (Ludvigsson JF. Gastroenterology 2017).

"In a nationwide population-based cohort study, we found endoscopy during pregnancy to be associated with increased risk of preterm birth or small for gestational age, but not of congenital malformation or stillbirth. However, these risks are small and likely due to intrafamilial factors or disease activity.

Adverse pregnancy outcomes are rare in women undergoing endoscopy during pregnancy. Potential excess risks, if any, seem minimal and should be weighed against the need for timely investigation and treatment of women where an underlying GI disease may be a more severe threat to pregnancy outcome than the endoscopy."

[ÀÌÁØÇà comment]

ÀӽŽà ³»½Ã°æ¿¡ ´ëÇؼ­´Â ÇÑ »êºÎÀΰú ±³¼ö´ÔÀÇ ±ÛÀ» Âü°íÇϽñ⠹ٶø´Ï´Ù.

³»½Ã°æ °ü·Ã ¾à¹°ÀÇ FDA µî±ÞÀº ¾Æ·¡¿Í °°½À´Ï´Ù.

Cotton and William's Practical Gastrointestinal Endoscopy (7ÆÇ, 29ÂÊ)¿¡´Â ¾Æ·¡¿Í °°ÀÌ ¾ð±ÞµÇ¾î ÀÖ½À´Ï´Ù.

"Pregnancy and lactation: Although this area has not been extensively studied, meperidine alone is preferred for procedural sedation during pregnancy. Midazolam, although listed as caterogy D by the US FDA, can be used in small doses in combination with meperidine. If deep sedation is required it should performed by an anesthesiologist. Concentrations of sedatives and analgesics vary in breast milk after procedureal administration. In general, breast-feeding may be continued after fentanyl administration, which is perferred over meperidine during lactation. Infants should not be breast-fed for at least 4 hours following maternal administration of midazolam."

[Àú³Î 2] Waist to hip ratio is a better predictor of esophageal acid exposure than body mass index


2017-2-28.

³»½Ã°æ ºÎºÐº° ÇöȲ Á¡°Ë (2): ÀÔ¿øȯÀÚ ³»½Ã°æ (ÀÌÇõ) - À§¾Ï preop clipping, ´ëÀå¾Ï polypectomy, ½Äµµ¾Ï RT clipping ¿øÄ¢ Á¤ÇÏ¿´À½.

À§¾Ïº´¼Ò°¡ À§Ã¼Áߺο¡ ÀÖÀ» ¶§¿¡´Â subtotal gastrectomyÀÇ ÀýÁ¦¸éÀ» Á¤Çϱ⠾î·Æ±â ¶§¹®¿¡, ¼ö¼ú Àü ³»½Ã°æ Ŭ¸®ÇÎÀÌ ÇÊ¿äÇÕ´Ï´Ù. º´¼ÒÀÇ proximal edge º¸´Ù 1 cm »ó¹æ¿¡ 2°³ÀÇ Å¬¸³À» ³ª¶õÈ÷ ºÙ¿©¼­ À§Ä¡½ÃÅ°´Â ¹æ¹ýÀ» ±ÇÇÕ´Ï´Ù. ÀÌ·¸°Ô ÇÏ¿´À» ¶§ ¼ö¼úÀå¿¡¼­ °¡Àå Àß ¸¸Á®Áø´Ù°í ÇÕ´Ï´Ù.

½Äµµ¾Ï RT Àü clippingÀ» ¿äû¹ÞÀ¸¸é À§¾Ï°ú ºñ½ÁÇÏ°Ô º´¼Ò °æ°è 1cm ÁöÁ¡¿¡ Ŭ¸³À» 2°³¾¿ À§Ä¡½Ãŵ´Ï´Ù. Proximal marginº¸´Ù 1 cm proximal¿¡ µÎ °³, distal marginº¸´Ù 1 cm distal¿¡ µÎ °³.

µÅÁö stomach ÀÌ¿ëÇÑ ESD ½Ç½ÀÀÏÁ¤À» Àâ¾ÆÁÖ¼¼¿ä.

ÇÐȸ Áý´ãȸ ¹ßÇ¥ÀÚ


3¿ù´Þ ±èÀçÁØ ±³¼ö´Ô ÀÏ¹Ý ³»½Ã°æ teaching session (º»°ü ±Ý¿äÀÏ ¿ÀÀü)

Áõ·Ê: RUQ pain (acute pancreatitis at ectopic pancreas)

³»½Ã°æ½Ç transition

³»½Ã°æ °á°ú ÀÛ¼º ½Ã °ú°Å ±â·Ï ditto ÇÒ ¶§ ÁÖÀÇ ¹Ù¶ø´Ï´Ù. Á¶Á÷°Ë»ç¸¦ ÇÏÁö ¾Ê¾Ò´Âµ¥ "Bx (+)"¶ó°í °á°ú°¡ ³ª°¬´ø °æ¿ì°¡ ÀÖ¾ú½À´Ï´Ù. 3/2 (ÙÊ) Á¡½É½Ã°£¿¡ ±èÀº¶õ ±³¼ö´Ô ´ÙÀ© °ü·Ã ±³À°

Ç×Ç÷¼ÒÆÇÁ¦, Ç×ÀÀ°íÁ¦ Àç°øÁö ¿¹Á¤ (±èÀº¶õ ±³¼ö´Ô). ´Ü¼øÈ÷ ÆÇ´ÜÇϱ⠾î·Á¿î ȯÀÚ´Â ±³¼ö´Ô²² consult Çϵµ·Ï µ¹·ÁÁֽñ⠹ٶø´Ï´Ù.

Box simulator ±³À°

³»½Ã°æ °£È£ ¼¼¹Ì³ª 3¿ù 14ÀÏ (Debriefing 3¿ù 17ÀÏ ±Ý¿äÀÏ)


2017-2-21.

³»½Ã°æ ºÎºÐº° ÇöȲ Á¡°Ë (1): ÁßȯÀÚ½Ç/¼ö¼úÀå (¹Î¾ç¿ø) - 1³â 343°Ç. NJ tube »ðÀÔ¹ý ±³À°.

3¿ù º»°ü ³»½Ã°æ½Ç ¿ÀÀü ¿ÀÈÄ supervisor ¿ªÇÒ ³íÀÇ - ÀÏÁ¤Àº ±èÀº¶õ ±³¼ö²²¼­ °øÁöÇÏ¿´À½.

[Áõ·Ê]

½Äµµ¾Ï + esophageal varix ¿´´ø ȯÀÚ¿¡¼­ bleeding historyÀº ¾ø¾úÁö¸¸ EVLÀ» ¸ÕÀú ÇÑ ÈÄ ESD°¡ Àß ½ÃÇàµÇ¾ú½À´Ï´Ù.

[Àú³Î ¸®ºä]

1) ³»½Ã°æ ÁöÇ÷¼ú ÈÄ ÀçÃâÇ÷¿¡ ´ëÇÑ ´Ù±â°ü ¿¬±¸°¡ ¹ßÇ¥µÇ¾ú½À´Ï´Ù (Jensen DM. Am J Gastroenterol 2017). ¿À·¡ µÈ ¿¬±¸ÀÇ post hoc analysisÀε¥ Forrest Ib°¡ »ý°¢¸¸Å­ À§ÇèÇÏÁö ¾Ê¾Æ¼­ PPI¸¦ °è¼Ó ½á¾ß ÇÏ´ÂÁö ´Ù½Ã °í·ÁÇØ º¸ÀÚ´Â °á·ÐÀ̾ú½À´Ï´Ù.

2) POEM after failed Heller myotomy (Ngamruengphong S. CGH 2017). ´Ù±¹Àû ´Ù±â°ü ¿¬±¸·Î Heller myotomy Çß´ø ȯÀÚ¿¡¼­µµ POEMÀ» Àß ½ÃÇàÇÒ ¼ö ÀÖ´Ù´Â ³»¿ëÀÔ´Ï´Ù. »ï¼º¼­¿ïº´¿ø¿¡¼­´Â ÇöÀç(2017/2)±îÁö 20¿¹ÀÇ POEM ½Ã¼ú °æÇèÀÌ ÀÖ½À´Ï´Ù.


2017-2-14.

³»½Ã°æ ºÎºÐº° ÇöȲ Á¡°Ë

¿ÜºÎ ÀÚ¿ø ÀÌ¿ë ³»½Ã°æ ½Ç½À arrange + alpha


[Àú³Î ¸®ºä 1] Stanley. BMJ 2017

ÀüÅëÀûÀ¸·Î ³»½Ã°æ ¼Ò°ßÀÎ Forrest ºÐ·ù°¡ ÀÚÁÖ ÀÌ¿ëµÇ¾î ¿Ô½À´Ï´Ù. ¾ÆÁ÷µµ ³»½Ã°æ Ä¡·á Çʿ伺À» ÆÇ´ÜÇϴµ¥´Â À¯¿ëÇÑ ÁöÇ¥ÀÔ´Ï´Ù.

óÀ½ ¿ÔÀ» ¶§ shockÀ̾ú´ø »ç¶÷°ú vitalÀÌ stable ÇÏ¿´´ø ȯÀÚÀÇ Ä¡·á´Â ÀüÇô ´Þ¶óÁ®¾ß ÇÕ´Ï´Ù. ±×·±µ¥ Forrest ºÐ·ù¿¡´Â ÀÓ»ó ¼Ò°ßÀÌ ¹Ý¿µµÇ¾î ÀÖÁö ¾Ê½À´Ï´Ù. µû¶ó¼­ ÀÔ¿øȯÀÚÀÇ ¿¹ÈÄ ¿¹Ãø°ú Ä¡·á °èȹ ¼ö¸³¿¡´Â Rockall systemÀ» Âü°íÇÏ°í ÀÖ½À´Ï´Ù. Composite score º¸´Ù´Â ¿¹ÈÄ ÀÎÀÚ Çϳª Çϳª¿¡ °ü½ÉÀ» ÁÖ´Â °ÍÀÌÁö¿ä. ±è¹üÁø ¼±»ý´ÔÀÇ µµ¿òÀ¸·Î ¿©·¯ scoring systmeÀ» ºñ±³ÇØ º» Àûµµ ÀÖÁö¸¸ ´Ùµé ºñ½ÁÇϹǷΠRockallÀ» ÁÖ·Î ¾²°í ÀÖ½À´Ï´Ù.

Rockall scoring system

±è¹üÁø. Dig Dis Sci 2009

2017³â BMJ¿¡ ¿©·¯ scoring systemÀ» ºñ±³ÇÑ ³í¹®ÀÌ ¶Ç ¹ßÇ¥µÇ¾ú½À´Ï´Ù (Stanley. BMJ 2017). Glasgow Blatchford score 1Àº ³»½Ã°æ Ä¡·áµµ ÇÊ¿äÇÏÁö ¾Ê°í outcomeµµ ÁÁÀ¸´Ï ¿Ü·¡¿¡¼­ Ä¡·áÇÒ ¼ö ÀÖ´Ù´Â °á·ÐÀ̾ú½À´Ï´Ù. "The Glasgow Blatchford score ¡Â1 appear the optimum threshold for directing patients to outpatient management." ¸»ÇÏÀÚ¸é ºóÇ÷ÀÌ ¾ø°í melena¸¸ ÀÖ¾ú´ø »ç¶÷Àº ¿Ü·¡¿¡¼­ Ä¡·áÇÒ ¼ö ÀÖ´Ù´Â À̾߱âÀÔ´Ï´Ù.

Glasgow Blatchford score

Stanley. BMJ 2017

[Àú³Î ¸®ºä 2] Negative deep resection margin¿¡ ´ëÇÑ Iwate Medical SchhoÀÇ ³í¹® (Toya. GIE 2016)

Lymphatic positive¶óµµ deep resection marginÀÌ À½¼ºÀÌ°í SM2¸é ÃßÀû°üÂû ÇÒ ¼ö ÀÖ´Ù´Â ³»¿ëÀε¥... ´Ù¼Ò ¿ì·Á½º·´½À´Ï´Ù. Sample size°¡ ³Ê¹« À۱⵵ ÇÏ°í.

Surgery (group A) versus observation (group B)


2017-2-7.

¸®ºä 1 (Â÷¶ó¸®) - Serum pepsinogen level after ESD for EGC - 14%¿¡¼­ metachronous cancer°¡ ¹ß»ýÇÏ¿´´Ù. H. pylori eradication after ESD did not affect development of metachronous gastric cancer (MGC).

¹ßÇ¥ ¿ä·É¿¡ ´ëÇÑ comment°¡ ÀÖ¾ú½À´Ï´Ù. (EndoTODAY ³í¹®°ú °­ÀǸ¦ À§ÇÑ ±×·¡ÇÈ À̹ÌÁö °ü¸®)

Áõ·Ê: ESRD, hematochezia

Data: ESD À§¾Ï complete resection 89%


2017-1-31.

¸®ºä 1 (Ç¥Á¤ÀÇ): NOAC

¸®ºä 2 (±èÁö¿ø): Primary GI T cell lymphoma
- Indolent T cell lymphoma´Â 2016³â ºÐ·ù¿¡ µé¾î¿ÔÀ½

Áõ·Ê (Ȳ±Ýºû): MMF »ç¿ë ÁßÀÎ ½Å°æ°ú ȯÀÚÀÓ. CMV esophagitis. MMF »ç¿ëÁßÀ̹ǷΠIV ganciclovir (ºñº¸Çè, ÇÏ·ç¿¡ ¾à 10¸¸¿ø) ¾²´Ù°¡ valganciclovir 900mg bid·Î º¯°æÇÏ¿´À½. Áõ»ó Áö¼ÓµÇ¾î ³»½Ã°æ Àç°ËÇÏ¿´À» ¶§ ´Ù¸¥ ºÎÀ§ÀÇ punchout ulcer°¡ ³ª¿È. Á¶Á÷ÇÐÀû Áõ°Å´Â ¾ø¾úÀ¸³ª IV ganciclovir → valganciclovir »ç¿ë ÇÏ´Ù Áß´Ü ÈÄ ÃßÀû³»½Ã°æÀ» ÇÏ¿´Àºµ¥ ±Ë¾çÀº ÀÖÀ½. ¾àÀ» ¾î¶»°Ô ¾µ °ÍÀΰ¡? CMV antigenemia À½¼ºÀ̹ǷΠFoscarnetÀ̳ª cidofovir¸¦ ¾²Áö´Â ¾Ê°í ÀÖÀ½. MMF¿Í °ü·ÃÀÌ ÀÖÀ»±î?
- ¶Ç Áõ»óÀ» µ¿¹ÝÇÑ CMV esophagitis·Î È®ÀεǸé (1) IV ganciclovir¸¦ ¾²°Å³ª (2) foscarnetÀ» ¾²°Å³ª (3) MMF¸¦ ´Ù¸¥ ¾àÀ» ¹Ù²ãº¼ ¼ö ÀÖÀ»±î?
- CMV gastritisµµ Áö¼ÓµÇ´Â °æ¿ì°¡ ÀÖ´Ù.

(1) ER ȯÀÚ (±èÅÂÁØ), (2) ÀÔ¿øȯÀÚ (ÀÌÇõ), (3) ÁßȯÀÚ½Ç ¹× portable ³»½Ã°æ (¹Î¾ç¿ø) °ü¸® Áöħ


2017-1-17.

Áõ·Ê 1: fundus EGC IIb·Î ÀǷڵǾúÀ¸³ª (1) fundus¿¡¼­´Â ¾ÏÀÌ ³ª¿ÀÁö ¾Ê¾Ò°í (2) ÀüÁ¤ºÎ¿¡¼­ Ãß°¡·Î ¾ÏÀÌ ¹ß°ßµÊ. (1) ºÎÀ§´Â °æ°ú°üÂû, (2) ºÎÀ§´Â ESD¸¦ ½ÃÇàÇÔ. → fundus lesion¿¡ ´ëÇؼ­´Â close follow up Çϱâ·Î ÇÔ

Áõ·Ê 2: gastric cancer with orbit

Àú³Î ¸®ºä: Endoscopy timing in peptic ulcer bleeding patients

±âŸ: ¿ù¿äÁý´ãȸ ¿î¿µ°èȹ

© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng.